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ABSTRACT: Nonsymmetric DiPPro-nucleotides are de-
scribed as nucleoside diphosphate (NDP) delivery systems.
The concept is to attach different bis(acyloxybenzyl) moieties
at the β-phosphate moiety of a NDP. DiPPro compounds
bearing two alkanoylbenzyl residues and DiPPro compounds
bearing an alkanoylbenzyl or a benzoylbenzyl group as
bioreversible prodrug moieties were studied. Compounds
bearing short chain alkanoyl esters led to a fast hydrolysis by
chemical or enzymatic means. The ester group in the second
prodrug group comprised a long lipophilic aliphatic or an
aromatic residue. The lipophilicity of this group enabled the
prodrug to penetrate the cell membrane. The introduction of
two different groups allowed a controlled stepwise removal of
the prodrug moieties to achieve a highly selective delivery of the NDP in CEM cell extracts. The compounds were highly active
against HIV even in thymidine kinase-deficient CEM cells. Thus, the compounds, although charged at the α-phosphate group,
were taken up by the cells and released NDPs.
■ INTRODUCTION
Nucleoside analogues are extensively used as agents in antiviral
and antitumor chemotherapy. However, their biological activity
is strongly dependent on their intracellular activation by host
cell kinases to give, via the mono- and the diphosphate, the
ultimately active triphosphate derivative which inhibits the
function of the viral DNA polymerase. However, in the case of
nucleoside analogues cellular kinases often catalyze these
metabolic steps insufficiently.1,2 The result might be a partial
loss of antiviral activity or for some nucleoside analogues even a
complete failure to exhibit any antiviral activity. Moreover,
inefficient phosphorylation led in some cases to adverse
effects.3,4 The use of prodrug forms of phosphorylated
nucleoside analogues (pronucleotides) can circumvent rate
limiting steps within the metabolic pathway by bypassing at
least one, if not several, involved activating enzymes.5,6 This
task has been successfully achieved in the past for the
intracellular delivery of monophosphates of nucleoside
analogues using prodrug strategies such as the cycloSal-,7−9
Sate-,10,11 bisPOM-12 and phosphoramidate-nucleotide ap-
proaches.13,14
Remarkably, in contrast to numerous examples of successful
nucleoside monophosphate prodrug approaches for the bypass
of nucleoside kinases, the development of nucleoside
diphosphate (NDP) prodrugs has been very rarely addressed.
However, such a prodrug approach might be desirable, for
instance, in the case of 3′-azido-3′-deoxythymidine (AZT),
which is very poorly phosphorylated from AZTMP to yield
AZTDP by thymidylate kinase (TMP-K) in human cells.15,16
Hostetler et al. synthesized different nucleoside diphosphate
diglycerides as potential NDP prodrugs.17−20 However, the
hydrolysis of these compounds delivered the monophosphates
instead of the diphosphates as a result of the cleavage of the
diphosphate moiety. A second approach was reported by
Huynh-Dinh et al.21−23 In their approach, the β-phosphate was
acylated with fatty acids forming a mixed anhydride bond. In
chemical hydrolysis studies the NDP was formed. However, in
cell extracts an undefined decomposition of the compounds
was observed.
Since a few years, we turned our interest toward the
bioreversible protection of nucleoside diphosphates although,
as compared to nucleoside monophosphate prodrugs, the
design of such compounds is more demanding because of a
chemical reason. In NDPs, a complete lipophilic modification
of the charged and therefore highly polar diphosphate unit led
to a considerable decrease in chemical stability of this part of
the molecule. As a result, the phosphate anhydride bond of the
nucleoside diphosphate was cleaved leading to two mono-
phosphorylated fragments.
Earlier, we reported on the DiPPro approach. In this
approach, esterification of the β-phosphate of a NDP with two
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bis(acyloxybenzyl) moieties neutralizes the charges at this
phosphate group. In previous studies this was achieved by
masking the β-phosphate using two identical bis-
(alkanoyloxybenzyl)24,25 or bis(benzoyloxybenzyl) moieties26
(symmetrical modification, R1 = R2). The concept was based on
an enzyme-driven cleavage of these masking units, which
ensured that the release of NDPs preferably took place
intracellularly because of the higher concentrations of the
esterases/lipases in the target cells. In contrast to the low
stability in the presence of esterases, the chemical stability at
physiological pH was still found to be high. By choosing the
appropriate substituent R in the ester moiety within the mask, it
was possible to “tune” both stability and lipophilicity of the
prodrugs (Scheme 1).25
Although we were able to prove that this approach works, an
unwanted property of the symmetric aliphatic or aromatic
DiPPro compounds was that also some nucleoside mono-
phosphate (NMP) was detected in addition to the wanted
nucleoside diphosphate, e.g., in PBS solution, pH 7.3, or cell
extract hydrolysis studies. Interestingly, it was shown that the
amount of NMP clearly correlated with the stability of the
DiPPro compounds and that the stability of the compounds
was dependent on the length of the alkyl residues R attached
via an ester linkage to the 4-hydroxybenzyl group: the longer
the alkyl group R, the higher was the stability of the DiPPro
compounds but the higher was also the amount of NMP
formed in the chemical hydrolyses and in the cell extract
studies. As the reason for the formation of NMP, a concurrence
reaction was identified in which water/hydroxide reacted at the
phosphorus atom of the β-phosphate group. This led to the
cleavage of the phosphate anhydride bond releasing the NMP.
This side reaction became more relevant with increasing
stability of the ester linkage in the prodrug moiety. On the
other hand, we observed that after the removal of the first mask
to give a monomasked intermediate such as 2, no further
increase of the amount of NMP was observed (Scheme 1). The
reason here was that after the first removal an additional charge
appeared at the β-phosphate, and this obviously prevented a
nucleophilic reaction at this moiety.
Taking all previous results together, these findings led to the
development of a second generation of DiPPro compounds.
Here, we disclose a study on a series of nonsymmetric DiPPro-
nucleotides 1 bearing two different masking units (R1 not equal
to R2). The design was the following: One masking group
contained a short alkyl chain carboxylic acid ester which,
because of our previously reported data,25 will be rapidly
cleaved by chemical or enzymatic means. The second masking
group contained a long alkyl residue carboxylic acid ester or a
substituted benzoic acid ester, which adds high lipophilicity to
the molecule. It was expected that such a construct would allow
a rapid conversion of the DiPPro compound 1 into the
monomasked intermediate 2 and thereby should avoid the side
reaction to form the unwanted nucleoside monophosphate.
The second mask will be cleaved subsequently from the
intermediate to form the nucleoside diphosphate. It was
expected that with these nonsymmetric compounds a highly
selective conversion of the DiPPro compounds into nucleoside
diphosphates can be achieved.
■ RESULTS AND DISCUSSION
Synthesis. For the synthesis of nonsymmetric DiPPro-
NDPs 1, we first tried to use the protocol of the symmetric
counterparts.24−26 According to that protocol, an amount of 2
equiv of an appropriate 4-acyloxybenzyl alcohol was reacted
with dichloro-N,N-diisopropylaminophosphoramidite to give
the corresponding phosphoramidite like 5 (R1 = R2) which was
then coupled by an acid-mediated reaction with a nucleoside
monophosphate followed by oxidation. For the new non-
symmetric compounds an attempt was made to introduce two
different 4-acyloxybenzyl masking units 3 and 4 by the same
way. However, this approach failed.
Scheme 1. Hydrolysis of earlier reported symmetric bis(acyloxybenzyl)-DiPPro compounds 1.
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Scheme 2. Synthesis of Nonsymmetric DiPPro-NDPs 7−10a
a(i) (a) 1 equiv of 3, 1 equiv of pyridine, −78 °C to rt, 24 h, THF; (b) 6.1 equiv of N,N-diisopropylamine, −10 °C to rt, 24−48 h, THF; (ii) 0.67
equiv of 4, 0.67 equiv of DCI-activator solution (0.25 M in acetonitrile), 4 °C to rt, 30−60 min, acetonitrile; (iii) (a) 1 equiv of [N(nC4H9)4]d4TMP
or [N(nC4H9)4]AZTMP, 1.5 equiv of 5, 1.25−1.75 equiv of DCI-activator solution (0.25 M in acetonitrile), rt, 30 min, acetonitrile; (b) 1.5 equiv of
t-BuOOH solution (5.5 M in n-decane), rt, 15 min, acetonitrile. Indices shown in compound 5, 6, and 7−10 are used for NMR assignment in
Experimental Section.
Figure 1. Nonsymmetric DiPPro-d4TDPs 7, 8 and DiPPro-ATZDPs 9, 10.
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Finally, in a new protocol 4-acyloxybenzyl alcohol 3 was
reacted with phosphorus trichloride followed by the addition of
2 equiv of N,N-diisopropylamine (DIPA) which led to
bis(diisopropylamino)phosphoramidites 6 in yields up to 56%
in a one-pot reaction. Then, one of the diisopropylamino
moieties was replaced by the second 4-acyloxybenzyl alcohol 4
after activation with dicyanoimidazol (DCI) to yield the
nonsymmetric phosphoramidites 5 in very high yields.
Next, a second acid-activated coupling of these phosphor-
amidites 5 with the corresponding nucleoside monophosphates
was carried out. At the beginning, the conversions obtained in
this coupling reaction were surprisingly low, which was proven
by NMR and HPLC analyses of the crude mixtures. Changing
the equivalents of phosphoramidite 5 and the DCI activator did
not led to an improvement. Finally, the problem was solved by
the successive addition of small amounts of the DCI-activator
solution. Starting with the addition of 0.5 equiv of DCI-
activator solution to a solution of 1 equiv of the nucleoside
monophosphate and 1.5 equiv of the phosphoramidite 5,
followed by the stepwise addition of 0.25 equiv every 5 min up
to a total of 1.25 or 1.75 equiv of DCI led to a quantitative
conversion of the nucleotide. DiPPro-nucleotides 7−10 were
successfully isolated by using automated flash RP-18-
chromatography. By use of the new protocol, numerous
combinations of DiPPro-nucleotides were accessible in
quantitative conversions, high isolated yields, and high purity,
which was checked by means of 1H, 13C, and 31P NMR
spectroscopy, mass spectrometry, and HPLC analysis. The
route for the synthesis of nonsymmetric DiPPro-NDPs 7−10 is
summarized in Scheme 2.
Structural formulas of DiPPro-d4TDPs 7, 8 and DiPPro-
AZTDPs 9, 10 bearing different aliphatic (R2 = CnH2n+1) and
aromatic (R2 = X-Ph) acyl moieties as the lipophilic masks in
combination with short aliphatic acyl moieties (R1= CH3,
C4H9) in the acyloxybenzyl-masking group are summarized in
Figure 1. Also three symmetric DiPPro-AZTDPs 11a−c were
prepared by the earlier published method.
Hydrolysis Studies. All prepared compounds were studied
with regard to their stabilities and their hydrolysis products in
different media.
Chemical Stability in Phosphate Buffer, pH 7.3. We
expected that the more labile mask would be cleaved faster to
form intermediate 2 bearing the long, lipophilic, and hydro-
lytically more stable mask. However, surprisingly in the
chemical hydrolysis studies in most of the cases both
intermediates were observed by means of HPLC analysis. In
the monomasked intermediates 2, the short alkanoyl ester
moieties were more rapidly hydrolyzed as compared to the long
alkyl bearing moieties. Furthermore, the half-lives determined
in phosphate buffer, pH 7.3, of the nonsymmetric DiPPro
compounds were surprisingly higher as compared to those of
the symmetric DiPPro-NDPs. This can be seen for example for
compound 7b (CH3/C9H19-DiPPro-d4TDP). In this case the
half-life of the cleavage of the first masking group bearing the
acetate group was 40 h while the same masking group in the
symmetrical di-CH3-DiPPro-d4TDP was cleaved with a half-life
of 10 h only.24 Steric hindrance or aggregation due to the
second, more lipophilic moiety might be a reason for this
increase in stability. The determined half-lives of the formation
of the monomasked intermediate were between 15 and 69 h as
summarized in Table 1.
The chemical stabilities of DiPPro-AZTDPs 9, 10 were in the
same range as those of the DiPPro-d4TDPs 7, 8 having
identical prodrug moieties. Only CH3/C11H23-DiPPro-AZTDP
9c showed a lower stability compared to the corresponding
d4TDP derivative 7c for some unknown reasons. Even in
comparison with the DiPPro compounds with shorter alkyl
chains the stability of CH3/C11H23-DiPPro-AZTDP 9c was
markedly low. Nevertheless, all DiPPro compounds 7−10
hydrolyzed in buffer to form almost exclusively the nucleoside
diphosphate.
As reported before, some NMP was formed as well probably
because of the unexpected high hydrolytic stability compared to
the symmetric DiPPro compounds bearing short alkyl chains in
the masking group. It is important to mention that the ratio of
NDP to NMP in these chemically driven hydrolyses was higher
as described for the symmetric compound with longer
chains.24,25
We also evaluated the chemical stability of DiPPro-AZTDP
9b and 10b in Roswell Park Memorial Institute (RPMI)
medium in addition to PBS solution, pH 7.3, as described
above. Both compounds showed also under these conditions
high stability (t1/2 = 19 h for 9b and t1/2 = 77 h for 10b) and
were found to be markedly more stable as compared to the
CEM/0 cell extracts.
Incubations in Cell Extracts of Wild Type CD4
+ T-
Lymphocyte Cells (CEM/0 Cell Extracts). As in the above-
described studies in PBS and RPMI culture medium, the half-
lives of the DiPPro compounds were found to be independent
of the nucleoside analogue attached to the molecule. In contrast
to the chemical hydrolysis studies, the prodrugs delivered the
corresponding nucleoside diphosphate selectively within 2−7 h
Table 1. Half-Lives of DiPPro-d4TDPs 7, 8 and DiPPro-AZTDPs 9, 10 in PBS and CEM/0 Cell Extracts
NDP = d4TDP 7 NDP = AZTDP 9
compd t1/2 [h] in PBS t1/2 [h] in CEM/0 t1/2 [h] in PBS t1/2 [h] in CEM/0
CH3/C7H15-DiPPro-NDP 7a/9a 36 0.04 33 0.02
CH3/C9H19-DiPPro-NDP 7b/9b 40 0.04 35 0.04
CH3/C11H23-DiPPro-NDP 7c/9c 48 0.16 32 0.11
CH3/CF3-Ph-DiPPro-NDP 7d/9d 15 0.03 13 0.04
CH3/CH3-Ph-DiPPro-NDP 7e 58 0.04
NDP = d4TDP 8 NDP = AZTDP 10
compd t1/2 [h] in PBS t1/2 [h] in CEM/0 t1/2 [h] in PBS t1/2 [h] in CEM/0
C4H9/C7H15-DiPPro-NDP 8a/10a 36 0.71 46 0.83
C4H9/C9H19-DiPPro-NDP 8b/10b 40 1.05 50 1
C4H9/C11H23-DiPPro-NDP 8c/10c 52 1.91 63 1.65
C4H9/CF3-Ph-DiPPro-NDP 8d/10d 15 0.88 19 0.83
C4H9/CH3-Ph-DiPPro-NDP 8e 50 0.96 - -
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only. In the case of the CH3/R
2-DiPPro-NDPs 7 and 9 the
hydrolysis led exclusively to the intermediates bearing the long
lipophilic acyl group with half-lives of minutes (Table 1). In all
cases the acetate ester was selectively cleaved first. However, in
comparison the cell extract hydrolysis of the C4H9/R
2-DiPPro-
NDPs 8 and 10 released in addition to the intermediate bearing
the long alkyl chain acyl group also the C4H9 intermediate,
although in a markedly smaller ratio. This is due to the higher
stability of the pentanoyl (R1 = C4H9) ester moiety compared
to the acetate group present in compounds 7 and 9. But also in
these cases the diphosphate was finally formed from both
intermediates selectively. The more lipophilic mask had no
influence on the half-lives of the cleavage of the short chain acyl
group (R1 = CH3 and R
1 = C4H9, respectively, Table 1) except
for the four DiPPro-nucleotides with R2 = C11H23 (7c−10c)
which showed different stabilities. Figure 2 summarizes as an
example the hydrolysis of CH3/C9H19-DiPPro-d4TDP 7b in
CEM/0 cell extracts followed by means of RP-18 HPLC. After
60 min virtually all of the prodrug 7b was consumed. Only the
C9H19 intermediate 11b and d4TDP appeared as hydrolysis
products at that time point. Whether traces of d4TMP were
also formed remained unclear because the detection of d4TMP
was not possible by RP-18 HPLC because of remaining cell
extract components that eluted in the chromatogram with
identical retention time. On the other hand, by use of a HILIC
column (HILIC: hydrophilic interaction liquid chromatogra-
phy) in the chromatography, the separation of d4TMP from
cell extract components was successful. With this second
analytical method it was proven that very small amounts of
d4TMP were also present in the CEM cell extract hydrolysis
samples of the DiPPro compounds.
In order to study if the detected d4TMP resulted either from
the side reaction described above or from a dephosphorylation
of d4TDP to give d4TMP due to phosphatases present in the
extracts, both d4TDP and AZTDP were incubated as well in
the CEM/0 cell extracts and aliquots of the hydrolysis mixtures
were analyzed after 2, 4, 7, and 10 h of incubation. In both cases
d4TMP and AZTMP were detected. The half-life of
dephosphorylation of d4TDP was 10 h, while that of AZTDP
was 19 h in the experimental setup. For this reason, we
concluded that the trace amounts of the nucleoside mono-
phosphates found in the above-described hydrolysis studies of
the DiPPro compounds in CEM/0 cell extracts were most likely
a result of a dephosphorylation of the formed diphosphates
from the prodrugs.
In the case of the C4H9/R
2-DiPPro-nucleotides 8 and 10 the
hydrolysis proceeded via both possible intermediates and then
led to the corresponding NDPs. As the half-lives for the starting
DiPPro compounds 1 bearing an acetyl (R1 = CH3) or a
pentanoyl (R1 = C4H9) residue, the half-lives for the formed
monomasked intermediates of type 2 were dependent on the
acyl ester group. The half-lives of monomasked intermediates
were determined by the decrease of the corresponding peak
areas in the HPL-chromatograms of these compounds in the
hydrolysis mixtures of the CH3/R
2-DiPPro-nucleotides 7 and 9
in CEM/0 cell extracts after full consumption of the starting
DiPPro compounds. The results are summarized in Table 2.
We assumed that the stability would increase with longer
chain length. Interestingly, intermediates 2a and 2′a were more
stable than the ones with longer chain length. Therefore, it
Figure 2. RP-18 HPLC chromatograms of the hydrolysis of CH3/C9H19-DiPPro-d4TDP 7b in CEM/0 cell extracts.
Table 2. Half-Lives of the Intermediates 2 and 2′ in CEM/0
Cell Extracts
t1/2 [min] in CEM/0
intermediate (with R2) 2 NDP = d4TDP 2′ NDP = AZTDP
C7H15 2a/2′a 99 99
C9H19 2b/2′b 50 50
C11H23 2c/2′c 69 63
Ph-CF3 2d/2′d 690 230
Ph-CH3 2e 870
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seemed that the octanoyl group was a worse substrate for the
ester cleaving enzymes.
In the case of the CF3-Ph intermediate 2d it is surprising that
the attached nucleoside had an influence on the stability. The
AZT intermediate 2′d was markedly more labile than the d4T
intermediate 2d for unknown reasons.
Incubations with Pig Liver Esterase. The nonsymmetric
aliphatic DiPPro-AZTDPs 9a−c and 10a−c bearing a R1 = CH3
or C4H9 in combination with long alkyl chains as the R
2 residue
were incubated with pig liver esterase (PLE) to investigate the
influence of the chain length on the enzymatic cleavage by this
esterase. Furthermore, CH3/C9H19-DiPPro-d4TDP 7b and
C4H9/C9H19-DiPPro-d4TDP 8b were also included to study
whether the attached nucleoside analog has an effect on the
hydrolysis pathway or on the compound stability.
The results of the hydrolysis experiments in the presence of
PLE are summarized in Table 3.
All compounds were rapidly hydrolyzed and delivered the
nucleoside diphosphates d4TDP or AZTDP exclusively within
a few minutes. The half-lives determined for the CH3/C7H15
and CH3/C9H19 compounds 9a,b as well as the C4H9/C7H15
and C4H9/C9H19-masked pronucleotides 10a,b were found to
be all in the same range (0.21−0.27 min). The influence of the
nucleoside on the half-live was small, although DiPPro-d4TDPs
7b and 8b proved to be somewhat less stable. In contrast, both
compounds 9c, and 10c (CH3/C11H23- and C4H9/C11H23-
DiPPro-AZTDP) bearing the longest aliphatic chain showed
higher stability against hydrolysis by PLE.
Remarkably, in the case of the hydrolysis of all CH3/R
2-
DiPPro 9a−c, 7b, exclusively the hydrolysis intermediate
bearing the long aliphatic chain was formed although in very
small amounts. Therefore, it was not possible to determine the
half-lives of these intermediates from the hydrolysis mixtures.
This means that both alkanoyl esters were cleaved at almost
identical rates, although with a slight preference of the C1-
alkanoyl group. As an example, the HPL-chromatograms of the
incubations of compound 9b with PLE are shown in Figure 3.
In contrast, incubation of C4H9/R
2-DiPPro-NDPs 10a−c, 8b
with PLE initially showed high amounts of the C4H9-
intermediate (Figure 4, e.g., the 1 min HPLC chromatogram).
In addition, as for the C7H15 and C11H23 intermediate, the
C9H19-chain bearing intermediate 2′b was also detected in the
HPL-chromatograms although to a minor extent. In contrast to
the above study with the CH3-bearing DiPPro compounds, here
obviously the longer lipophilic chain acyl groups are cleaved
faster than the C4H9-alkanoyl ester. This can be concluded
from the markedly different amounts of the two possible
intermediates in the HPL-chromatograms (Figure 4). From
both formed intermediates AZTDP was finally released with a
half-life of about 19 min as the sole hydrolysis product.
These observations contrasted also with the results obtained
in CEM/0 cell extracts and point to a different substrate
Table 3. Half-Lives of the DiPPro Compounds 7−10 in the
Presence of PLE
t1/2 [min] of
compd DiPPro-NDP R1 intermediate
CH3/C9H19-DiPPro-d4TDP 7b 0.14 nm.
a
CH3/C7H15-DiPPro-AZTDP 9a 0.26 nm.
a
CH3/C9H19-DiPPro-AZTDP 9b 0.21 nm.
a
CH3/C11H23-DiPPro-AZTDP 9c 0.45 nm.
a
C4H9/C9H19-DiPPro-d4TDP 8b 0.19 28
C4H9/C7H15-DiPPro-AZTDP 10a 0.27 15
C4H9/C9H19-DiPPro-AZTDP 10b 0.27 19
C4H9/C11H23-DiPPro-AZTDP 10c 1.2 38
anm.: not measurable.
Figure 3. RP-18-HPLC chromatograms of the PLE-mediated hydrolysis of CH3/C9H19-DiPPro-AZTDP 9b.
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specificity of the esterase from pig liver and the esterases
present in human CEM/0 cells or other enzymes that play a
significant role in the hydrolysis process of the DiPPro
compounds described here.
Comparative Hydrolysis Studies. Finally, we compared the
nonsymmetric DiPPro-nucleotides described here with com-
pounds 11 bearing identical masking groups. Therefore,
nonsymmetric and the symmetric counterparts DiPPro-
AZTDP derivatives with R = C4H9 (11a), C6H13 (11b), and
C9H19 (11c) were incubated in phosphate buffer at pH 7.3 and
in CEM/0 cell extracts. The hydrolysis studies in PBS led to
significant differences in the ratios of formed NDP and NMP.
In all cases the symmetric compounds 11 formed markedly
more NMP and less NDP as compared to the studies of the
nonsymmetric DiPPro compounds disclosed here. Even more
interesting was the comparison of the hydrolysis in CEM/0 cell
extracts. Also under these conditions the hydrolysis of the
symmetric C4H9-DiPPro-AZTDP 11a and C6H9-DiPPro-
AZTDP 11b resulted in high NDP/NMP ratios. In contrast,
this ratio decreased significantly in the case of the more
lipophilic C9H19-DiPPro-AZTDP 11c which was correlated to
the difference in the rate of metabolism. As mentioned above,
the short chain alkyl esters are rapidly cleaved by the esterases
present in the extracts, and therefore, the side reaction did not
interfere as in the case of the more stable long chain aliphatic
esters. Figure 5 summarizes a comparison of the hydrolysis of
CH3/C9H19-DiPPro-AZTDP 9b, C9H19-DiPPro-AZTDP 11c,
and the nucleoside diphosphate AZTDP after 10 h of
incubation. The analysis of the hydrolysis aliquots was
performed by means of HILIC-HPLC. The NDP/NMP ratio
in the case of the nonsymmetric prodrug 9b was found to be
5:1. For the symmetric prodrug 11c the ratio was only 1.5:1.
Interestingly, starting from independently synthesized AZTDP,
the ratio was found to be 3:1 after 10 h of incubation in CEM/0
cell extracts.
The markedly higher ratio found in the case of the
nonsymmetric DiPPro-prodrug 9b compared to AZTDP
implies that compound 9b is not susceptible to cleavage at
the pyrophosphate moiety. The formation of the NMP only
took place by the enzymatic dephosphorylation af ter AZTDP
delivery and thus after cleavage of the masking units. As a
consequence, the NDP/NMP ratio in the case of the prodrug
9b was even higher as compared to that of AZTDP for which
the dephosphorylation immediately starts at the beginning of
the incubation. On the other hand, because of the high stability
of the symmetric DiPPro compound 11c against enzymatic
cleavage of the prodrug moieties, the chemical cleavage of the
diphosphate unit in this compound occurred by the above-
described concurrence reaction which led to AZTMP and
consequently to a low NDP/NMP ratio (1.5:1).
Antiviral Activity. All DiPPro compounds 7−11 were
evaluated for their anti-HIV activity in HIV-1- and HIV-2-
infected wild-type CEM/0 cell cultures and in HIV-2-infected
Figure 4. RP-18-HPLC chromatograms of the PLE-mediated hydrolysis of C4H9/C9H19-DiPPro-AZTDP 10b.
Figure 5. HPL-chromatograms (HILIC column) of the incubations of
CH3/C9H19-DiPPro-AZTDP 9b, C9H19-DiPPro-AZTDP 11c, and
AZTDP in CEM/0 cell extracts after 10 h. The asterisk (∗) indicates
components from the cell extracts.
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mutant thymidine kinase-deficient CEM/TK− cell cultures.
Table 4 summarizes the antiviral and cytostatic data of the
DiPPro compounds 7−10 and the parent nucleoside analogues
d4T and AZT, respectively, as reference compounds.
D4TDP derivatives 7, 8 bearing aliphatic ester functions in
the acyloxybenzyl units (a−c) proved to be antivirally active
against HIV-1 and HIV-2 at least in the same concentration
range as compared to the parent compound d4T in wild-type
CEM/0 cell cultures. Often the inhibitory potency was even
somewhat higher as compared to that of the parent nucleoside
particularly for compound 8c. The antiviral activity observed in
the wild-type CEM/0 cell cultures was completely retained in
the case of the lipophilic DiPPro compounds 7b and 8b,c in
mutant thymidine-deficient CEM cells (TK−). Moreover, the
antiviral activity increased with the increase of lipophilicity
associated with the introduced acyl moieties of the DiPPro
prodrugs.
Disappointingly, DiPPro-d4TDPs 7, 8 bearing benzoyl ester
functions in the masking units (d, e) proved to be less potent as
compared to the alkanoyl counterparts. They also were less
active as compared to d4T in the wild-type CEM/0 cell cultures
and lost more or less all antiviral activity in the TK-deficient
CEM cell cultures (EC50 ≥ 10 μM).
Like the d4TDP-containing DiPPro compounds, the AZTDP
derivatives 9 and 10 were able to inhibit the HIV-1 and HIV-2
induced cytopathogenic effect at very low concentrations in
wild-type CEM/0 cell cultures.
In mutant thymidine kinase-deficient CEM/TK− cell cultures
only the lipophilic compounds 9c, 10b, and 10c showed some
antiviral activity (EC50 ≈ 10 μM). Interestingly, the symmetric
C9H19-DiPPro compound 11c was active at 1.3 μM in the TK-
deficient CEM cell cultures. One reason for this pronounced
retention of antiviral activity of 11c might be that the
lipophilicity of this compound was sufficiently high to allow a
passage through the cell membrane. In the hydrolysis studies
discussed above it was shown that all compounds bearing an
acetyl ester as an acyl moiety in the masking group were
cleaved extremely fast. Thus, if these compounds are not
lipophilic enough, they will be cleaved in the cell culture
medium before the uptake into the cells. Then AZTDP will be
formed extracellularly which will be enzymatically dephos-
phorylated to give AZT. AZT is able to migrate through the
membrane, and this results in antiviral activity in the wild-type
cell cultures. It has been reported that the phosphorylation of
AZTMP to AZTDP by dTMP kinase is rate-limiting.15,16
However, another reason for the failure of the DiPPro-AZTDP
compounds might be that even the delivered AZTDP is not
efficiently metabolized into the corresponding triphosphate. In
such a case the delivery of AZTDP will not lead to increased
antiviral activity. It was already reported that in biochemical
activity studies using nucleoside diphosphate kinase (NDP-K),
which is generally the enzyme that is involved in the
phosphorylation of nucleoside diphosphates into their
triphosphate forms, the phosphorylation to AZTTP was rather
poor.27 So maybe there is not only a bottleneck in the
metabolism of AZTMP to AZTDP28 but also a bottleneck in
the conversion of AZTDP to form AZTTP which becomes
more prominent if the concentration of AZTDP is increased
because of its delivery from a prodrug. From our studies in
CEM/0 cell extracts we clearly have proven that the exclusively
formed product from the prodrug was AZTDP.
Table 4. Anti-HIV and Cytostatic Activity of the DiPPro-NDPs 7−11
EC50
a [μM]
CEM/0 CEM/0 CEM/TK− CC50
b [μM]
compd HIV-1 (HE) HIV-2 (ROD) HIV-2 (ROD) CEM/0
CH3/C7H15-DiPPro-d4TDP 7a 0.33 ± 0.11 1.05 ± 0.30 6.31 ± 0.00 33 ± 27
CH3/C9H19-DiPPro-d4TDP 7b 0.33 ± 0.11 1.36 ± 0.13 2.32 ± 1.6 15 ± 1
CH3/C11H23-DiPPro-d4TDP 7c 0.29 ± 0.16 0.28 ± 0.04 1.77 ± 0.33 26 ± 0
CH3/CF3-Ph-DiPPro-d4TDP 7d 0.72 ± 0.16 1.38 ± 0.16 >10 51 ± 15
CH3/CH3-Ph-DiPPro-d4TDP 7e 0.29 ± 0.057 1.47 ± 0.29 10 ± 0.00 11 ± 6
C4H9/C7H15-DiPPro-d4TDP 8a 0.33 ± 0.11 1.47 ± 0.29 6.31 ± 0.00 66 ± 15
C4H9/C9H19-DiPPro-d4TDP 8b 0.36 ± 0.046 1.17 ± 0.40 0.83 ± 0.00 20 ± 1
C4H9/C11H23-DiPPro-d4TDP 8c 0.10 ± 0.03 0.28 ± 0.04 0.13 ± 0.07 30 ± 17
C4H9/CF3-Ph-DiPPro-d4TDP 8d 0.40 ± 0.00 0.72 ± 0.16 >10 37 ± 31
C4H9/CH3-Ph-DiPPro-d4TDP 8e 0.3 ± 0.014 1.45 ± 0.00 10 ± 0.00 14 ± 1
CH3/C7H15-DiPPro-AZTDP 9a 0.042 ± 0.008 0.16 ± 0.08 >10 29 ± 3
CH3/C9H19-DiPPro-AZTDP 9b 0.016 ± 0.0 0.14 ± 0.08 >10 20 ± 9
CH3/C11H23-DiPPro-AZTDP 9c 0.042 ± 0.008 0.08 ± 0.00 10 ± 2.61 18 ± 3
CH3/CF3-Ph-DiPPro-AZTDP 9d 0.012 ± 0.007 0.06 ± 0.03 >10 100 ± 8
C4H9/C7H15-DiPPro-AZTDP 10a 0.036 ± 0.0 0.07 ± 0.01 >10 73 ± 12
C4H9/C9H19-DiPPro-AZTDP 10b 0.034 ± 0.018 0.29 ± 0.18 10 ± 0.00 41 ± 23
C4H9/C11H23-DiPPro-AZTDP 10c 0.013 ± 0.005 0.06 ± 0.02 8.16 ± 2.61 36 ± 28
C4H9/CF3-Ph-DiPPro-AZTDP 10d 0.036 ± 0.0 0.06 ± 0.02 >10 58 ± 54
C4H9-DiPPro-AZTDP 11a 0.011 ± 0.0018 0.054 ± 0.01 >10 60 ± 7
C6H13-DiPPro-AZTDP 11b 0.016 ± 0.0 0.058 ± 0.03 >10 47 ± 8
C9H19-DiPPro-AZTDP 11c 0.026 ± 0.014 0.23 ± 0.15 1.3 ± 0.0 38 ± 10
d4T 0.52 ± 0.32 2.23 ± 1.51 150 ± 9 79 ± 3
AZT 0.044 ± 0.01 0.49 ± 0.57 >250 >250
aAntiviral activity in CEM T-lymphocyte cultures: 50% effective concentration. bCytostatic activity: 50% cytostatic concentration to inhibit CEM/0
cell proliferation by 50%.
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■ SUMMARY AND CONCLUSION
Nonsymmetric DiPPro-NDPs 1 of the anti-HIV active
nucleoside analogues d4T and AZT are disclosed here bearing
two different masking units attached to the β-phosphate group
of the corresponding nucleoside diphosphate. For the synthesis
of the title compounds, a new protocol for the synthesis of
nonsymmetric bis(acyloxybenzyl)phosphoramidites was devel-
oped, which yielded the phosphoramidites in high chemical
yields. These were coupled by weak acid catalysis with
nucleoside monophosphates followed by oxidation. By use of
this route, DiPPro-d4TDP and DiPPro-AZTDP compounds
with different combinations of aliphatic and aromatic acyl
moieties were obtained in good yields. Hydrolysis studies in
phosphate buffer, RPMI-culture medium, CEM/0 cell extracts,
and pig liver esterase confirmed the designed delivery
mechanism described above. Half-lives in PBS and RPMI-
culture medium were markedly higher than those in CEM/0
cell extracts and incubations with PLE. Although in PBS still
both the nucleoside diphosphates and the monophosphates
were formed, the exclusive products formed by enzymatic
hydrolysis of the prodrugs (cell extracts and PLE) were the
nucleoside diphosphates. As compared to the symmetric
DiPPro-NDPs with two identical masks reported previously,
the ratio of formed NDP to NMP was markedly higher in all
media. Most of the nonsymmetric DiPPro compounds were as
active as or even more active than the corresponding parent
nucleosides in wild-type CEM/0 cell cultures. Moreover, also
high activities were obtained depending on the lipophilicity of
the DiPPro-d4TDP prodrugs against HIV-2 in mutant CEM/
TK− cell cultures. This confirmed that these compounds were
efficiently taken up by the cells and delivered intracellularly a
phosphorylated form of d4T, most likely d4T diphosphate.
Surprisingly, the good antiviral activities of DiPPro-AZTDPs in
the wild-type cell cultures were only weakly retained in the
mutant TK-deficient cell cultures. This may point to a possible
further bottleneck in the phosphorylation of the AZTDP to
AZTTP. A clear conclusion from the antiviral activity data was
that DiPPro compounds bearing short acetyl ester or benzoyl
ester groups in one of the prodrug moieties were not suitable
for further development. The first ester group is cleaved too fast
and is not lipophilic enough to allow a successful uptake into
the target cells, while the second type of ester moiety is also not
lipophilic enough although we have shown before that the
stability of such compounds could be adjusted over a wide
range.26 Nevertheless, this report on nonsymmetric DiPPro
compounds proved the successful and selective nucleoside
diphosphate delivery as a further development of the DiPPro-
approach.
■ EXPERIMENTAL SECTION
General. All experiments involving water-sensitive compounds
were conducted under anhydride conditions and nitrogen atmosphere.
All solvents were dried over an appropriate drying agent. Triethyl-
amine and acetonitrile were dried by heating under reflux over calcium
hydride for several days followed by distillation. Acetonitrile was
stored over 3 Å molecular sieves. THF was dried by heating under
reflux over potassium followed by distillation. Petroleum ether 50−70
for chromatography was distilled before use. The evaporation of
solvents was carried out on a rotary evaporator under reduced pressure
or using a high-vacuum pump. Preparative radial chromatography was
performed by chromatotron (Harrison Research, model 7924T) with
glass plates coated with 1, 2, or 4 mm layers of VWR 60 PF254 silica gel
containing a fluorescent indicator (VWR no. 7749). Analytical thin-
layer chromatography was performed on precoated aluminum plates
with a 0.2 mm layer of silica gel containing a fluorescent indicator
(Macherey & Nagel Xtra Sil UV254); sugar-containing compounds
were visualized by wetting the plates with 10% sulfuric acid in water
and heating with a fan.
Instrumentation. 1H NMR spectroscopy was carried out using a
Bruker AMX 400 or AV 400 at 400 MHz or a Bruker AV 600 at 600
MHz with CDCl3 or MeOD-d4 as internal standards.
13C NMR spectra
were recorded on a Bruker AMX 400 or AV 400 at 101 MHz or on a
Bruker AV 600 at 150 MHz (CDCl3 or MeOD-d4 as internal
standard). 31P NMR spectra were recorded on a Bruker AMX 400 at
162 MHz or a Bruker AV 600 at 243 MHz (H3PO4 as internal
standard). 19F NMR spectra were recorded on a Bruker AV 600 MHz.
All 1H, 31P, and 13C NMR chemical shifts are quoted in parts per
million (ppm). All 13C and 31P NMR spectra were recorded in the
proton-decoupled mode. High resolution ESI mass spectra were
recorded with an Agilent 6224 ESI-TOF spectrometer in positive or
negative modes. MALDI mass spectra were recorded on an
ultrafleXtreme MALDI-TOF-TOF mass spectrometer by Bruker
Daltonik with 9-AA as matrix. All HPLC measurements were carried
out using a VWR Hitachi “Elite LaChrom” (pump L-2130,
autosampler L-2200, column oven L-2300, diode array detector L-
2455). Analytical Rp18-HPLC: Macherey & Nagel EC 125/3
NUCLEODUR 100-5 C18 EC. As e luent s CH3CN/
[(C4H9)4N]
+CH3COO
− buffer (2 mM, pH 6.0) gradient was used.
Method A: 0−24 min CH3CN (5−80%), 24−29 min CH3CN (80%),
flow rate 1 mL/min. Method B: 0−27 min CH3CN (5−90%), 27−30
min CH3CN (90%), flow rate 1 mL/min, column temperature of 25
°C. UV detection at 265 nm. The purities of the DiPPro nucleotides
were evaluated by means of HPLC and were in all cases ≥95%.
Analytical HILIC-HPLC: Macherey & Nagel EC 125/4 NUCLEO-
DUR HILIC, 5 μm. As eluents, CH3CN/NH4
+HCOO− buffer (10
mM, pH 8.3) gradient was used. Method C: 0−5 min CH3CN (95%),
5−15 min CH3CN (95−70%), 15−30 min CH3CN (70%), flow rate
0.6 mL/min, column temperature of 25 °C. UV detection at 265 nm.
Synthesis. General Procedure A. Preparation of Acylox-
ybenzyl Bis(diisopropylamino)phosphoramidite 6. To a low
concentrated solution of 1 equiv of phosphorus trichloride and 1 equiv
of pyridine in THF, 1 equiv of 4-acyloxybenzyl alcohol dissolved in
THF was added dropwise over 1.5 h at −78 °C. After removal of the
cold bath the reaction was stirred for about 20 h at room temperature
until the total reaction of 4-acyloxybenzyl alcohol was accomplished.
Then an amount of 6.1 equiv of N,N-diisopropylamine was added
dropwise at −10 °C. After removal of the cold bath the reaction was
stirred for about 1−2 days at room temperature. Salts were removed
by filtration. The crude product was purified by radial chromatography
at the chromatotron with petroleum ether/triethylamine as eluent.
General Procedure B. Preparation of Nonsymmetric Bis-
(acyloxybenzyl)phosphoramidites 5. To a solution of 1.5 equiv of
phosphordiamidite in acetonitrile, 1 equiv of 4-acyloxybenzyl alcohol
and 1 equiv of a DCI-activator solution (0.25 M in acetonitrile) also
dissolved in acetonitrile were added dropwise at 4 °C. After removal of
the cold bath the reaction mixture was stirred for 30−60 min. The
reaction was stopped by removing the solvent under reduced pressure.
The residue was dissolved in petroleum ether/triethylamine (9:1) and
filtered. The crude product was purified by radial chromatography at
the chromatotron with petroleum ether/triethylamine as eluent.
General Procedure C. Preparation of DiPPro-Nucleoside
Diphosphates. An amount of 1.5 equiv of phosphoramidite 5 was
added to a solution of 1 equiv of the bis(tetra-n-butylammonium)
nucleoside monophosphate in acetonitrile. The reaction was started by
addition of 0.5 equiv of 4,5-dicyanoimidazole (0.25 M solution in
acetonitrile) at room temperature. Every 5 min again 0.25 equiv of 4,5-
dicyanoimidazole was added up to a total of 1.25−1.75 equiv. After
stirring another 5 min after the last addition, the mixture was oxidized
by addition of 1.5 equiv of tert-butyl hydroperoxide (5.5 M solution in
n-decane). The solvents were removed under reduced pressure after
15 min. The compounds were isolated by automatic flash RP18-
chromatography (acetonitrile/water). After the tetra-n-butylammo-
nium ions were changed with ammonia by elution over DOWEX
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50WX8 (NH4
+), a second automatic flash RP18 chromatography
(acetonitrile/water) followed.
Syntheses of 4-(hydroxymethyl)phenylacetate 3a ,24 4-
(hydroxymethyl)phenylpentanoate 3b,25 4-(hydroxymethyl)-
phenyloctanoate 4a,24 4-(hydroxymethyl)phenyldecanoate 4b,25 4-
(hydroxylmethyl)phenyldodecanoate 4c,25 4-(hydroxymethyl)phenyl-
4′-trifluoromethylbenzoate 4d,26 4-(hydroxymethyl)phenyl-4′-methyl-
benzoate 4e,26 and 4-(hydroxymethyl)phenylheptanoate 4f25 have
been described before. The analytical data were identical to those
reported before.
Syntheses of (N[n-Bu]4)2-d4TMP and (N[n-Bu]4)2-AZTMP have
been described before.24,25 The analytical data were identical to those
reported before.
Acetoxybenzyl Bis(diisopropylamino)phosphoramidite 6a.
General procedure B; 4-acyloxybenzyl alcohol 3a (2.36 g, 14.4 mmol),
dissolved in 15 mL of THF and phosphorus trichloride (1.26 mL, 14.4
mmol) and pyridine (1.17 mL, 14.4 mmol) in 35 mL of THF. In the
following step DIPA (12.4 mL, 87.8 mmol) was added. The product
(3.02 g, 7.62 mmol, 53%) was obtained as a colorless waxlike solid. 1H
NMR (400 MHz, CDCl3): δ [ppm] = 7.39−7.37 (m, 2 H, H-2);
7.05−7.04 (m, 2 H, H-3); 4.64−4.63 (m, 2 H, Ph-CH2); 3.61−3.54
(m, 4 H, CN-H); 2.29 (s, 3 H, H-6); 1.19 (d, 3JH,H = 6.9 Hz, 12 H,
isoPr); 1.19 (d, 3JH,H = 7.0 Hz, 12 H, isoPr).
13C NMR (101 MHz,
CDCl3): δ [ppm] = 169.6 (C-5); 149.6 (C-4); 138.3 (d,
3JC,P = 10.6
Hz, C-1); 127.9 (C-2); 121.3 (C-3); 65.6 (d, 2JC,P = 23.2 Hz, Ph-
CH2); 44.5 (d,
1JC,N = 12.3 Hz, 2 × N-CH); 24.7 (d,
2JC,N = 8.0 Hz,
isoPr); 24.0 (d, 2JC,N = 5.6 Hz, isoPr); 21.2 (C-6).
31P NMR (162
MHz, CDCl3, decoupled): δ/ppm =123.4; IR ν̃ [cm
−1] = 2970, 2923,
2901, 1766, 1506, 1454, 1302, 1114, 1049, 950, 741. MS (MALDI) m/
z = calcd for C34H46N3O6P: 589.331 [M − H+ + 9-aminoacridine (9-
AA) used as matrix]−. Found: 589.309.
P en t a n o y l o x y b en z y l B i s ( d i i s o p r op y l am i n o ) -
phosphoramidite 6b. General procedure B; 4-acyloxybenzyl alcohol
3b (2.25 g, 10.8 mmol), dissolved in 15 mL of THF and phosphorus
trichloride (0.94 mL, 10.8 mmol) and pyridine (0.88 mL, 10.8 mmol)
in 35 mL of THF. In the following step DIPA (9.24 mL, 65.8 mmol)
was added. The product (2.65 g, 6.04 mmol, 56%) was obtained as a
colorless oil. 1H NMR (400 MHz, CDCl3): δ [ppm] = 7.38−7.36 (m,
2 H, H-2); 7.04−7.02 (m, 2 H, H-3); 4.64−4.62 (m, 2 H, Ph-CH2);
3.62−3.52 (m, 4 H, CN-H); 2.29 (t, 3JHH = 7.5 Hz, 2 H, H-6); 1.78−
1.70 (m, 2H, H-7); 1.50−1.40 (m, 2H, H-8); 1.18 (d, 3JH,H = 6.8 Hz,
12 H, isoPr); 1.18 (d, 3JH,H = 6.9 Hz, 12 H, isoPr); 0.97 (t,
3JH,H = 7.4
Hz, 2 H, H-9). 13C NMR (101 MHz, CDCl3): δ [ppm] = 172.5 (C-5);
149.7 (C-4); 138.2 (d, 3JC,P = 10.7 Hz, C-1); 127.9 (C-2); 121.3 (C-
3); 65.7 (d, 2JC,P = 23.0 Hz, Ph-CH2); 44.6 (d,
1JC,N = 12.4 Hz, 2 × N-
CH); 34.3 (C-6); 27.2 (C-7); 24.8 (d, 2JC,N = 7.9 Hz, isoPr); 24.0 (d,
2JC,N = 5.7 Hz, isoPr); 22.4 (C-8); 13.9 (C-9).
31P NMR (162 MHz,
CDCl3, decoupled): δ/ppm =123.5. IR ν̃ [cm
−1] = 2964, 2930, 2870,
1760, 1507, 1390, 1195, 1182, 1144, 1016, 951, 779. MS (MALDI) m/
z = calcd for C37H52N3O6P: 631.386 [M + 9-aminoacridine (9-AA)
used as matrix]. Found: 631.368.
CH3/C7H15-phosphoramidite 5a. General procedure C;
acetoxybenzylbis(diisopropylamino)phosphoramidite 6a (1.24 g, 3.12
mmol) dissolved in 15 mL of acetonitrile and 4-(hydroxymethyl)-
phenyloctanoate 4a (520 mg, 2.08 mmol) and DCI-activator solution
(8.32 mL, 2.08 mmol) dissolved in 5 mL of acetonitrile. The product
(932 mg, 1.71 mmol, 82%) was obtained as a colorless oil. 1H NMR
(400 MHz, CDCl3): δ [ppm] = 7.36−7.34 (m 4H, H-2, H-2′); 7.05−
7.03 (m, 4H, H-3, H-3′); 4.77−4.73 (m, 2H, Ph-CH2); 4.70−4.66 (m,
2H, Ph-CH2); 3.72−3.66 (m, 2H, 2 × NC-H); 2.56−2.53 (m, 2H, H-
6′); 2.29 (s, 3H, −CH3); 1.78−1.73 (m, 2H, H-7′); 1.44−1.29 (m,
12H, H-8′−H-11′); 1.20 (d, 3JH,H = 6.8 Hz, 12H, isoPr); 0.90 (d, 3JH,H
= 6.8 Hz, 3H, H-12′). 13C NMR (101 MHz, CDCl3): δ [ppm] = 172.5
(C-5′); 169.6 (C-5); 150.1 (C-4′); 150.0 (C-4); 137.3 (d, 3JC,P = 7.6
Hz, C-1′); 137.1 (d, 3JC,P = 7.5 Hz, C-1); 128.1, 128.1 (C-2, C-2′);
121.5, 121.5 (C-3, C-3′); 65.0 (d, 2JC,P = 4.7 Hz, Ph-CH2); 64.9 (d,
2JC,P = 4.8 Hz, Ph-CH2); 43.3 (d,
1JC,N = 12.5 Hz, N-CH); 34.6 (C-6′);
31.8, 29.2, 29.6, 22.7, (C-8′−C-11′); 25.1 (C-7′); 24.8, 24.8 (2 ×
isoPr); 21.3 (C-6); 14.2 (C-12′). 31P NMR (162 MHz, CDCl3,
decoupled): δ/ppm =148.0. IR ν̃ [cm−1] = 2965, 2929, 2859, 1760,
1608, 1507, 1366, 1192, 1163, 1005, 973, 756, 504. HRMS (ESI+) m/z
= calcd for C30H45NO6P: 546.2979 [M + H
+]+. Found: 546.2951.
CH3/C9H19-phosphoramidite 5b. General procedure C;
acetoxybenzylbis(diisopropylamino)phosphoramidite 6a (520 mg,
1.31 mmol) dissolved in 10 mL of acetonitrile and 4-(hydroxymethyl)-
phenyldecanoate 4b (244 mg, 0.88 mmol) and DCI-activator solution
(3.52 mL, 0.88 mmol) dissolved in 6 mL of acetonitrile. The product
(437 mg, 0.76 mmol, 87%) was obtained as a colorless oil. 1H NMR
(400 MHz, CDCl3): δ [ppm] = 7.36−7.34 (m 4H, H-2, H-2′); 7.05−
7.02 (m, 4H, H-3, H-3′); 4.77−4.64 (m, 4H, 2 × Ph-CH2); 3.73−3.64
(m, 2H, 2 × NC-H); 2.56−2.52 (m, 2H, H-6′); 2.29 (s, 3H, −CH3);
1.79−1.71 (m, 2H, H-7′); 1.44−1.27 (m, 12H, H-8′−H-13′); 1.20 (d,
3JH,H = 6.8 Hz, 12H, isoPr); 0.89 (d,
3JH,H = 6.8 Hz, 3H, H-14′). 13C
NMR (101 MHz, CDCl3): δ [ppm] = 172.5 (C-5′); 169.6 (C-5);
150.2 (C-4′); 150.0 (C-4); 137.2 (d, 3JC,P = 7.4 Hz, C-1, C-1′); 128.2,
128.1 (C-2, C-2′); 121.5, 121.5 (C-3, C-3′); 65.1 (d, 2JC,P = 3.2 Hz,
Ph-CH2); 64.9 (d,
2JC,P = 3.4 Hz, Ph-CH2); 43.3 (d,
1JC,N = 12.4 Hz,
N-CH); 34.6 (C-6′); 32.0, 29.6, 29.4, 29.3, 22.8, (C-8′−C-13′); 25.1
(C-7′); 24.8, 24.8 (2 × isoPr); 21.3 (C-6); 14.2 (C-14′). 31P NMR
(162 MHz, CDCl3, decoupled): δ/ppm =148.0. IR ν̃ [cm
−1] = 2964,
2926, 2855, 1759, 1507, 1192, 1005, 972, 755, 503. HRMS (ESI+) m/z
= calcd for C32H49NO6P: 574.3292 [M + H
+]+. Found: 574.3196.
CH3/C11H23-phosphoramidite 5c. General procedure C;
acetoxybenzylbis(diisopropylamino)phosphoramidite 6a (620 mg,
1.57 mmol) dissolved in 12 mL of acetonitrile and 4-(hydroxymethyl)-
phenyldodecanoate 4c (319 mg, 1.04 mmol) and DCI-activator
solution (4.16 mL, 1.04 mmol) in 5 mL of acetonitrile. The product
(453 mg, 0.75 mmol, 72%) was obtained as a colorless oil. 1H NMR
(400 MHz, CDCl3): δ [ppm] = 7.36−7.33 (m 4H, H-2, H-2′); 7.05−
7.02 (m, 4H, H-3, H-3′); 4.78−4.64 (m, 4H, 2 × Ph-CH2); 3.73−3.64
(m, 2H, 2 × NC-H), 2.56−2.52 (m, 2H, H-6′); 2.29 (s, 3H, -CH3);
1.78−1.71 (m, 2H, H-7′); 1.43−1.26 (m, 16H, H-8′−H-15′); 1.20 (d,
3JH,H = 6.8 Hz, 12H, isoPr); 0.89 (d,
3JH,H = 6.8 Hz, 3H, H-16′). 13C
NMR (101 MHz, CDCl3): δ [ppm] = 172.5 (C-5′); 169.5 (C-5);
150.2 (C-4′); 150.0 (C-4); 137.2 (C-1, C-1′); 128.2 (C-2, C-2′); 121.5
(C-3, C-3′); 65.0 (d, 2JC,P = 18.4 Hz, Ph-CH2); 65.0 (d, 2JC,P = 18.9
Hz, Ph-CH2); 43.3 (d,
1JC,N = 12.2 Hz, N-CH); 34.6 (C-6′); 29.8,
29.7, 29.6, 29.5, 29.4, 29.4, 29.3 (C-8′−C-15′); 25.1 (C-7′); 24.8, 24.8
(2 × isoPr); 21.3 (C-6); 14.4 (C-16′). 31P NMR (162 MHz, CDCl3,
decoupled): δ/ppm =148.0. IR ν̃ [cm−1] = 2964, 2925, 2854, 1760,
1608, 1507, 1365, 1192, 1163, 1005, 973, 756, 503. HRMS (ESI+) m/z
= calcd for C34H53NO6P: 602.3605 [M + H
+]+. Found: 602.4100.
CH3/CF3-Ph-phosphoramidite 5d. General procedure C;
acetoxybenzylbis(diisopropylamino)phosphoramidite 6a (544 mg,
1.37 mmol) dissolved in 12 mL of acetonitrile and 4-(hydroxymethyl)-
phenyl-4′-trifluoromethylbenzoate 4d (271 g, 0.915 mmol) and DCI-
activator solution (3.66 mL, 0.915 mmol) in 5 mL of acetonitrile. The
product (360 mg, 0.61 mmol, 67%) was obtained as a colorless oil. 1H
NMR (400 MHz, CDCl3): δ [ppm] = 8.33−8.32 (m 2H, H-7′); 7.79−
7.78 (m, 2H, H-8′); 7.43−7.41 (m, 2H, H-2′); 7.37−7.36 (m, 2H, H-
2); 7.19−7.18 (m, 2H, H-3′); 7.06−7.05 (m, 2H, H-3); 4.81−4.67 (m,
4H, 2 × Ph-CH2); 3.74−3.68 (m, 4H, CN-H); 2.29 (s, 3H, CH3); 1.22
(d, 3JH,H = 6.7 Hz, 6H, isoPr); 1.22 (d,
3JH,H = 6.5 Hz, 6H, isoPr).
13C
NMR (101 MHz, CDCl3): δ [ppm] = 169.7 (C-5); 164.2 (C-5′);
150.0 (C-4); 149.9 (C-4); 137.7 (d, 3JC,P = 7.5 Hz, C-1′); 137.2 (d,
3JC,P = 7.8 Hz, C-1); 135.2 (d,
3JC,F = 33 Hz, C-9′), 133.0 (C-6′); 130.7
(C-8′); 128.3 (C-2′); 128.3 (C-2); 125.8 (d, 3JC,F = 3.6 Hz, C-7′);
125.7 (CF3); 121.5, 121.5 (C-3, C-3′); 65.0 (d, 2JC,P = 18.5 Hz, Ph-
CH2); 65.0 (d,
2JC,P = 18.6 Hz, Ph-CH2); 43.2 (d,
1JC,N = 12.3 Hz, N-
CH); 24.8, 24.8 (d, 2JC,N = 7.3 Hz, 2 × isoPr); 21.3 (C-6).
19F NMR
(565 MHz, CDCl3): δ/ppm =67.1.
31P NMR (162 MHz, CDCl3,
decoupled): δ/ppm =148.1. IR ν̃ [cm−1] = 2968, 2932, 2869, 1762,
1741, 1608, 1506, 1324, 1264, 1193, 1129, 1075, 1013, 770, 552.
HRMS (ESI+) m/z = calcd for C30H34F3NO6P: 592.2071 [M + H
+]+.
Found: 592.2209.
CH3/CH3-Ph-phosphoramidite 5e. General procedure C;
acetoxybenzylbis(diisopropylamino)phosphoramidite 6a (505 mg,
1.27 mmol) dissolved in 10 mL of acetonitrile and 4-(hydroxymethyl)-
phenyl-4′-methylbenzoate 4e (205 mg, 0.85 mmol) and DCI-activator
solution (3.40 mL, 0.85 mmol) in 5 mL of acetonitrile. The product
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(323 mg, 0.60 mmol, 71%) was obtained as a colorless oil. 1H NMR
(400 MHz, CDCl3): δ [ppm] = 8.11−8.09 (m 2H, H-7′/H-8′); 7.42−
7.36 (m, 4H, H-2, H-2′); 7.32−7.30 (m, 2H, H-7′/H-8′); 7.19−7.17
(m, 2H, H-3′); 7.07−7.05 (m, 2H, H-3); 4.81- 4.67 (m, 4H, 2 × Ph-
CH2); 3.76−3.67 (m, 4H, CN-H); 2.45 (s, 3H, -Ph-CH3); 2.29 (s, 3H,
−CH3); 1.22 (d, 3JH,H = 6.8 Hz, 6H, isoPr); 1.22 (d, 3JH,H = 6.8 Hz,
6H, isoPr). 13C NMR (101 MHz, CDCl3): δ [ppm] = 169.6 (C-5);
165.4 (C-5′); 150.3 (C-4); 150.0 (C-4′); 144.5 (C-9′); 137.3 (d, 2JC,P
= 8.0 Hz, C-1/C-1′); 137.2 (d, 2JC,P = 7.8 Hz, C-1/C-1′); 130.3 (C-
7′); 129.4 (C-8′); 128.2, 128.2 (C-2/C-2′); 127.0 (C-6′); 121.7, 121.5
(C-3, C-3′); 65.0 (d, 2JC,P = 18.4 Hz, Ph-CH2); 65.1 (d, 2JC,P = 18.3
Hz, Ph-CH2); 43.3 (d,
1JC,N = 12.4 Hz, N-CH); 24.8, 24.8 (d,
2JC,N =
7.2 Hz, 2 × isoPr); 21.9 (Ph-CH3); 21.3 (C-6).
31P NMR (162 MHz,
CDCl3, decoupled): δ/ppm =147.9. IR ν̃ [cm
−1] = 2966, 2930, 2868,
1762, 1735, 1610, 1507, 1366, 1192, 1177, 1003, 972, 783, 505. HRMS
(ESI+) m/z = calcd for C30H37NO6P: 538.2553 [M + H
+]+. Found:
538.2359.
C4H9/C7H15-phosphoramidite 5f. General procedure C;
pentanoyloxybenzylbis(diisopropylamino)phosphoramidite 6b (350
mg, 0.798 mmol) dissolved in 8 mL of acetonitrile and 4-
(hydroxymethyl)phenyloctanoate 4a (133 mg, 0.532 mmol) and
DCI-activator solution (2.13 mL, 0.532 mmol) in 4 mL of acetonitrile.
The product (281 mg, 0.478 mmol, 90%) was obtained as a colorless
oil. 1H NMR (400 MHz, CDCl3): δ [ppm] = 7.35−7.34 (m 4H, H-2,
H-2′); 7.04−7.02 (m, 4H, H-3, H-3′); 4.76−4.73 (m, 2H, Ph-CH2);
4.69−4.65 (m, 2H, Ph-CH2); 3.72−3.65 (m, 2H, 2 × NC-H), 2.56 (t,
3JH,H = 6.4 Hz, 2H, H-6′); 2.54 (t, 3JH,H = 6.4 Hz, 2H, H-6); 1.76−1.72
(m, 4H, H-7, H-7′); 1.48−1.29 (m, 10H, H-8, H-8′ − 11′); 1.20 (d,
3JH,H = 6.8 Hz, 12H, isoPr); 0.97 (d,
3JH,H = 7.4 Hz, 3H, H-9); 0.89 (d,
3JH,H = 6.8 Hz, 3H, H-12′). 13C NMR (101 MHz, CDCl3): δ [ppm] =
172.5 (C-5, C-5′); 150.1 (C-4, C-4′); 137.1 (d, 3JC,P = 7.4 Hz, C-1, C-
1′); 128.2 (C-2, C-2′); 121.5 (C-3, C-3′); 65.0 (d, 2JC,P = 18.1 Hz, 2 ×
Ph-CH2); 43.3 (d,
1JC,N = 12.4 Hz, N-CH); 34.6, 34.3 (C-6, C-6′);
31.8, 29.2, 29.1, 22.8, 22.4 (C-8, C-8′−C-11′); 27.2, 25.1 (C-7, C-7′);
24.8, 24.8 (2 × isoPr); 14.2 (C-12′); 13.9 (C-9). 31P NMR (162 MHz,
CDCl3, decoupled): δ/ppm =148.0. IR ν̃ [cm
−1] = 2964, 2929, 2861,
1758, 1608, 1507, 1364, 1197, 1163, 1001, 973, 754, 504. HRMS
(ESI+) m/z = calcd for C33H51NO6P: 588.3449 [M + H
+]+. Found:
588.3379.
C4H9/C9H19-phosphoramidite 5g. General procedure C;
pentanoyloxybenzylbis(diisopropylamino)phosphoramidite 6b (427
mg, 0.974 mmol) dissolved in 8 mL of acetonitrile and 4-
(hydroxymethyl)phenyldecanoate 4b (181 mg, 0.649 mmol) and
DCI-activator solution (2.60 mL, 0.649 mmol) in 4 mL of acetonitrile.
The product (344 mg, 0.559 mmol, 86%) was obtained as a colorless
oil. 1H NMR (400 MHz, CDCl3): δ [ppm] = 7.35−7.34 (m 4H, H-2,
H-2′); 7.04−7.02 (m, 4H, H-3, H-3′); 4.76−4.73 (m, 2H, Ph-CH2);
4.69−4.65 (m, 2H, Ph-CH2); 3.72−3.65 (m, 2H, 2 × NC-H), 2.56 (t,
3JH,H = 6.8 Hz, 2H, H-6′); 2.54 (t, 3JH,H = 6.8 Hz, 2H, H-6); 1.77−1.72
(m, 4H, H-7, H-7′); 1.48−1.38 (m, 4H, H-8′, H-8); 1.35−1.26 (m,
10H, H-9′−H-13′); 1.20 (d, 3JH,H = 6.8 Hz, 12H, isoPr); 0.97 (d, 3JH,H
= 7.4 Hz, 3H, H-9); 0.89 (d, 3JH,H = 6.9 Hz, 3H, H-14′). 13C NMR
(101 MHz, CDCl3): δ [ppm] = 172.5 (C-5, C-5′); 150.1 (C-4, C-4′);
137.1 (d, 3JC,P = 7.6 Hz, C-1, C-1′); 128.2 (C-2, C-2′); 121.5 (C-3, C-
3′); 65.0 (d, 2JC,P = 18.1 Hz, 2 × Ph-CH2); 43.3 (d, 1JC,N = 12.6 Hz, N-
CH); 34.6, 34.3 (C-6, C-6′); 32.0, 29.6, 29.4, 22.8, (C-9′−C-13′); 29.3
(C-8/C-8′); 27.2, 25.1 (C-7, C-7′); 24.8, 24.8 (2 × isoPr); 22.4 (C-8/
C-8′); 14.2, 13.9 (C-9, C-14′). 31P NMR (162 MHz, CDCl3,
decoupled): δ/ppm =148.0. IR ν̃ [cm−1] = 2962, 2927, 2856, 1758,
1507, 1364, 1198, 1138, 1104, 973, 754, 504. HRMS (ESI+) m/z =
calcd for C35H55NO6P: 616.3762 [M + H
+]+. Found: 616.3753.
C4H9/C11H23-phosphoramidite 5h. General procedure C;
pentanoyloxybenzylbis(diisopropylamino)phosphoramidite 6b (376
mg, 1.08 mmol) dissolved in 8 mL of acetonitrile and 4-
(hydroxymethyl)phenyldodecanoate 4c (220 mg, 0.72 mmol) and
DCI-activator solution (2.88 mL, 0.72 mmol) in 4 mL of acetonitrile.
The product (174 mg, 0.242 mmol, 34%) was obtained as a colorless
oil. 1H NMR (400 MHz, CDCl3): δ [ppm] = 7.35−7.34 (m 4H, H-2,
H-2′); 7.04−7.02 (m, 4H, H-3, H-3′); 4.77−4.72 (m, 2H, Ph-CH2);
4.69−4.65 (m, 2H, Ph-CH2); 3.72−3.65 (m, 2H, 2 × NC-H), 2.57−
2.53 (m, 2H, H-6, H-6′); 1.78−1.71 (m, 4H, H-7, H-7′); 1.49−1.26
(m, 18H, H-8, H-8′−H-15′); 1.20 (d, 3JH,H = 6.8 Hz, 12H, isoPr); 0.97
(d, 3JH,H = 7.4 Hz, 3H, H-9); 0.88 (d,
3JH,H = 6.9 Hz, 3H, H-16′). 13C
NMR (101 MHz, CDCl3): δ [ppm] = 172.5 (C-5, C-5′); 150.0 (C-4,
C-4′); 136.9 (m, C-1, C-1′); 128.1 (C-2, C-2′); 121.5 (C-3, C-3′);
65.0 (d, 2JC,P = 18.1 Hz, 2 × Ph-CH2); 43.3 (d,
1JC,N = 12.5 Hz, N-
CH); 34.6, 34.3 (C-6, C-6′); 32.1, 29.7, 29.4, 29.3, 22.8, 22.4 (C8, C-
8′−C-13′); 27.1, 25.1 (C-7, C-7′); 24.8, 24.8 (2 × isoPr); 14.2 (C-
14′); 13.9 (C-9). 31P NMR (162 MHz, CDCl3, decoupled): δ/ppm =
148.0. IR ν̃ [cm−1] = 2962, 2925, 2855, 1758, 1507, 1311, 1198, 1138,
1004, 973, 755, 503. HRMS (ESI+) m/z = calcd for C37H59NO6P:
644.4075 [M + H+]+. Found: 644.4068.
C4H9/CF3-Ph-phosphoramidite 5i. General procedure C;
pentanoyloxybenzylbis(diisopropylamino)phosphoramidite 6b (717
mg, 1.64 mmol) dissolved in 12 mL of acetonitrile and 4-
(hydroxymethyl)phenyl-4′-trifluoromethylbenzoate 4d (323 mg, 1.09
mmol) and DCI-activator solution (4.36 mL, 1.09 mmol) in 5 mL of
acetonitrile. The product (622 mg, 0.981 mmol, 90%) was obtained as
a colorless oil. 1H NMR (400 MHz, CDCl3): δ [ppm] = 8.33−8.31 (m
2H, H-7′); 7.79−7.77 (m, 2H, H-8′); 7.43−7.41 (m, 2H, H-2′); 7.37−
7.35 (m, 2H, H-2); 7.19−7.17 (m, 2H, H-3′); 7.05−7.03 (m, 2H, H-
3); 4.81−4.66 (m, 4H, 2 × Ph-CH2); 3.75- 3.66 (m, 4H, CN-H); 2.56
(t, 3JH,H = 7.5 Hz, 2H, H-6); 1.78−1.70 (m, 2H, H-7); 1.49−1.40 (m,
2H, H-8); 1.22 (d, 3JH,H = 6.8 Hz, 6H, isoPr); 1.21 (d,
3JH,H = 6.8 Hz,
6H, isoPr); 0.97 (t, 3JH,H = 7.3 Hz, 2H, H-9).
13C NMR (101 MHz,
CDCl3): δ [ppm] = 172.4 (C-5); 164.1 (C-5′); 150.0 (C-4); 149.9 (C-
4′); 137.7 (C-1′); 137.1 (C-1); 135.0 (C-6′), 132.9 (C-9′); 130.7 (C-
7′); 128.3 (C-2′); 128.2 (C-2); 125.8 (d, 3JC,F = 3.7 Hz, C-8′); 125.5
(CF3); 121.5, 121.5 (C-3, C-3′); 65.0 (d, 2JC,P = 18.5 Hz, Ph-CH2);
65.0 (d, 2JC,P = 18.3 Hz, Ph-CH2); 43.2 (d,
1JC,N = 12.4 Hz, N-CH);
34.3 (C-6); 27.2 (C-7); 24.8, 24.8 (d, 2JC,N = 7.3 Hz, 2 × isoPr); 22.4
(C-8); 13.9 (C-9). 19F NMR (565 MHz, CDCl3): δ/ppm = 63.2.
31P
NMR (162 MHz, CDCl3, decoupled): δ/ppm = 148.1. IR ν̃ [cm
−1] =
2968, 2932, 2872, 1737, 1505, 1325, 1266, 1065, 1014, 969, 712, 504.
HRMS (ESI+) m/z = calcd for C33H40F3NO6P: 616.3692 [M + H
+]+.
Found: 616.3753.
C4H9/CH3-Ph-phosphoramidite 5j. General procedure C;
pentanoyloxybenzylbis(diisopropylamino)phosphoramidite 6b (396
mg, 0.903 mmol) dissolved in 8 mL of acetonitrile and 4-
(hydroxymethyl)phenyl-4′-methylbenzoate 4e (146 mg, 0.602
mmol) and DCI-activator solution (2.4 mL, 0.60 mmol) in 4 mL of
acetonitrile. The product (348 mg, 0.60 mmol, 99%) was obtained as a
colorless oil. 1H NMR (400 MHz, CDCl3): δ [ppm] = 8.10−8.08 (m
2H, H-7′/H-8′); 7.40−7.39 (m, 2H, H-2′); 7.36−7.35 (m, 2H, H-2);
7.31−7.30 (m, 2H, H-7′/H-8′); 7.17−7.16 (m, 2H, H-3′); 7.05−7.03
(m, 2H, H-3); 4.79−4.67 (m, 4H, 2 × Ph-CH2); 3.73−3.67 (m, 4H,
CN-H); 2.55 (t, 3JH,H = 7.5 Hz, 2H, H-6); 2.45 (s, 3H, -Ph-CH3);
1.76−1.71 (m, 2H, H-7); 1.48−1.41 (m, 2H, H-8); 1.21 (d, 3JH,H = 6.8
Hz, 6H, isoPr); 1.21 (d, 3JH,H = 6.7 Hz, 6H, isoPr); 0.97 (t,
3JH,H = 7.4
Hz, 2H, H-9). 13C NMR (101 MHz, CDCl3): δ [ppm] = 172.5 (C-5);
164.4 (C-5′); 150.3 (C-4); 150.1 (C-4′); 144.5 (C-9′); 137.2 (d, 2JC,P
= 7.6 Hz, C-1/C-1′); 137.2 (d, 2JC,P = 7.6 Hz, C-1/C-1′); 130.4 (C-
7′); 129.4 (C-8′); 128.2, 128.2 (C-2/C-2′); 127.0 (C-6′); 121.7, 121.5
(C-3, C-3′); 65.0 (d, 2JC,P = 18.2 Hz, Ph-CH2); 65.0 (d, 2JC,P = 18.1
Hz, Ph-CH2); 43.2 (d,
1JC,N = 12.4 Hz, N-CH); 34.3 (C-6); 27.2 (C-
7); 24.8, 24.8 (d, 2JC,N = 7.3 Hz, 2 × isoPr); 22.4 (C-8); 21.9 (Ph-
CH3); 13.9 (C-9).
31P NMR (162 MHz, CDCl3, decoupled): δ/ppm =
144.0. IR ν̃ [cm−1] = 2965, 2931, 2871, 1758, 1736, 1610, 1507, 1264,
1197, 1007, 972, 756, 506. HRMS (ESI+) m/z = calcd for
C33H43NO6P: 616.3692 [M + H
+]+. Found: 616.3753.
Syntheses of symmetric bis(4-pentanoyloxymethyl)-, bis(4-hepta-
noy loxymethy l ) - , and b i s (4 -decanoy loxymethy l ) -N ,N -
diisopropylaminophosphoramidite have been described before.24,25
The analytical data were identical.
Ammonium-CH3/C7H15-DiPPro-d4TDP 7a. General procedure
E; phosphoramidite 5a (144 mg, 0.26 mmol), d4T monophosphate
(110 mg, 0.18 mmol), and 4,5-dicyanoimidazole activator solution
(1.04 μL, 0.26 mmol) in 4 mL of acetonitrile. Oxidation by addition of
tert-butyl hydroperoxide (5.5 M solution in n-decane, 47 μL, 0.26
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mmol). The product (108 mg, 0.14 mmol, 79%) was obtained as a
colorless wad after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ
[ppm] = 7.76 (s, 1H, H-6); 7.41−7.37 (m, 4H, H-c, H-c′); 7.08−7.04
(m, 4H, H-d, H-d′); 6.95−6.95 (m, 1H, H-1′); 6.39−6.38 (m, 1H, H-
3′); 5.84−5.83 (m, 1H, H-2′); 5.12−5.09 (m, 4H, H-a, H-a′); 4.95 (bs,
1H, H-4′); 4.22−4.15 (m, 2H, H-5′); 2.58 (t, 3JH,H = 7.4 Hz, 2H, H-
g′); 2.27 (s, 3H, CH3); 1.89 (s, 3H, H-7); 1.73 (dt, 3JH,H = 7.4 Hz,
3JH,H = 7.4 Hz, 2H, H-h′); 1.45−1.29 (m, 8H, H-i′−H-l′); 0.92 (t,
3JH,H = 6.8 Hz, 3H, H-m′). 13C NMR (150 MHz, MeOH-d4): δ [ppm]
= 173.9 (C-f′); 171.2 (C-f); 166.7 (C-4); 152.8 (C-2); 152.5 (C-e, C-
e′); 138.7 (C-6); 135.3 (C-3′); 135.0 (C-b′, C-b); 130.4 (2 ×d, 4JC,P =
4.8 Hz, 4JC,P = 4.8 Hz, C-c, C-c′); 127.6 (C-2′); 122.9 (C-d, C-d′);
112.1 (C-5); 90.8 (C-1′); 86.9 (d, 3JC,P = 9.0 Hz, C-4′); 70.2 (d, 2JC,P =
5.2 Hz, C-a, C-a′); 67.2 (d, 3JC,P = 5.5 Hz, C-5′); 35.0 (C-g′); 32.9,
30.1, 30.1, 23.7 (C-i′−C-l′); 26.0 (C-h′); 20.9 (CH3); 14.4 (C-m′);
12.5 (C-7). 31P NMR (243 MHz, MeOH-d4, decoupled): δ/ppm =
−12.07 (d, 2JP,P = 20.0 Hz, 1P, Pβ); −12.92 (d, 2JP,P = 20.7 Hz, 1P, Pα).
HRMS (ESI+, m/z) calcd for C34H42N2O14P2Na: 787.2009 [M + Na]
+.
Found: 787.1983. RP18-HPLC: method A, tR = 17.1 min.
Ammonium-CH3/C9H19-DiPPro-d4TDP 7b. General procedure
E; phosphoramidite 5b (165 mg, 0.29 mmol), d4T monophosphate
(120 mg, 0.19 mmol), and 4,5-dicyanoimidazole activator solution
(1.14 mL, 0.29 mmol) in 4 mL of acetonitrile. Oxidation by addition
of tert-butyl hydroperoxide (5.5 M solution in n-decane, 53 μL, 0.29
mmol). The product (106 mg, 0.031 mmol, 54%) was obtained as a
colorless wad after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ
[ppm] = 7.66 (s, 1H, H-6); 7.41−7.37 (m, 4H, H-c, H-c′); 7.08−7.04
(m, 4H, H-d, H-d′); 6.95−6.95 (m, 1H, H-1′); 6.39−6.38 (m, 1H, H-
3′); 5.84−5.83 (m, 1H, H-2′); 5.12−5.09 (m, 4H, H-a, H-a′); 4.95 (bs,
1H, H-4′); 4.22−4.15 (m, 2H, H-5′); 2.58 (t, 3JH,H = 7.4 Hz, 2H, H-
g′); 2.27 (s, 3H, CH3); 1.89 (s, 3H, H-7); 1.72 (dt, 3JH,H = 7.4 Hz,
3JH,H = 7.5 Hz, 2H, H-h′); 1.44−1.30 (m, 12H, H-i′−H-n′); 0.91 (t,
3JH,H = 6.6 Hz, 3H, H-o′). 13C NMR (150 MHz, MeOH-d4): δ [ppm]
= 173.9 (C-f′); 171.1 (C-f); 166.7 (C-4); 152.8 (C-2); 152.5 (C-e, C-
e′); 138.7 (C-6); 135.3 (C-3′); 135.0 (C-b′, C-b); 130.4 (2 ×d, 4JC,P =
4.5 Hz, 4JC,P = 5.0 Hz, C-c, C-c′); 127.6 (C-2′); 122.9 (C-d, C-d′);
112.1 (C-5); 90.8 (C-1′); 86.9 (d, 3JC,P = 9.4 Hz, C-4′); 70.2 (C-a, C-
a′); 68.0 (d, 3JC,P = 6.2 Hz, C-5′); 35.0 (C-g′); 33.1, 30.6, 30.4, 30.2,
23.7 (C-i′−C-n′); 26.0 (C-h′); 20.9 (CH3); 14.4 (C-o′); 12.5 (C-7).
31P NMR (243 MHz, MeOH-d4, decoupled): δ/ppm = −12.07 (d,
2JP,P = 20.6 Hz, 1P, Pβ); −12.92 (d, 2JP,P = 20.5 Hz, 1P, Pα). HRMS
(ESI+, m/z) calcd for C36H46N2O14P2Na: 815.2322 [M + Na]
+.
Found: 815.2312. RP18-HPLC: method A, tR = 18.5 min.
Ammonium-CH3/C11H23-DiPPro-d4TDP 7c. General procedure
E; phosphoramidite 5c (108 mg, 0.18 mmol), d4T monophosphate
(77 mg, 0.12 mmol), and 4,5-dicyanoimidazole activator solution (720
μL, 0.18 mmol) in 4 mL of acetonitrile. Oxidation by addition of tert-
butyl hydroperoxide (5.5 M solution in n-decane, 33 μL, 0.18 mmol).
The product (24 mg, 0.028 mmol, 23%) was obtained as a colorless
wad after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ [ppm] =
7.66 (d, 4JH,H = 1.0 Hz, 1H, H-6); 7.41−7.37 (m, 4H, H-c, H-c′);
7.08−7.04 (m, 4H, H-d, H-d′); 6.94 (ddd, 3JH,H = 3.5 Hz, 3/4JH,H = 1.7
Hz, 3/4JH,H = 1.6 Hz, 1H, H-1′); 6.38 (ddd, 3JH,H = 6.0 Hz, 3JH,H = 3.2
Hz, 4JH,H = 3.2 Hz, 1H, H-3′); 5.83 (ddd, 3JH,H = 5.9 Hz, 3JH,H = 3.4
Hz, 4JH,H = 3.4 Hz, 1H, H-2′); 5.12−5.09 (m, 4H, H-a, H-a′); 4.94 (bs,
1H, H-4′); 4.23−4.15 (m, 2H, H-5′); 2.58 (t, 3JH,H = 7.4 Hz, 2H, H-
g′); 2.27 (s, 3H, CH3); 1.89 (d, 4JH,H = 1.0 Hz 3H, H-7); 1.73 (m, 2H,
H-h′); 1.45−1.29 (m, 12H, H-i′−H-p′); 0.90 (t, 3JH,H = 7.1 Hz, 3H,
H-q′). 13C NMR (150 MHz, MeOH-d4): δ [ppm] = 173.8 (C-f′);
171.1 (C-f); 166.5 (C-4); 152.8 (C-2); 152.3 (C-e, C-e′); 138.7 (C-6);
135.3 (C-3′); 134.9 (C-b′, C-b); 130.4 (2 ×d, 4JC,P = 4.6 Hz, 4JC,P =
5.2 Hz, C-c, C-c′); 127.6 (C-2′); 122.9 (C-d, C-d′); 112.1 (C-5); 90.8
(C-1′); 86.9 (d, 3JC,P = 9.1 Hz, C-4′); 70.2 (C-a, C-a′); 68.1 (d, 3JC,P =
6.6 Hz, C-5′); 35.0 (C-g′); 33.1, 30.7, 30.6, 30.5, 30.4, 30.2, 23.7 (C-
i′−C-p′); 26.0 (C-h′); 20.9 (CH3); 14.4 (C-q′); 12.5 (C-7). 31P NMR
(243 MHz, D2O, decoupled): δ/ppm = −12.08 (d, 2JP,P = 20.8 Hz,
Pβ); −12.92 (d, 2JP,P = 20.2 Hz, Pα). HRMS (ESI−, m/z) calcd for
C38H49N2O14P2: 819.2665 [M − H+]−. Found: 819.2604. RP18-
HPLC: method A, tR = 19.5 min.
Ammonium-CH3/CF3-Ph-DiPPro-d4TDP 7d. General procedure
E; phosphoramidite 5d (140 mg, 0.24 mmol), d4T monophosphate
(100 mg, 0.16 mmol), and 4,5-dicyanoimidazole activator solution
(960 μL, 0.24 mmol) in 4 mL of acetonitrile. Oxidation by addition of
tert-butyl hydroperoxide (5.5 M solution in n-decane, 44 μL, 0.24
mmol). The product (40 mg, 0.048 mmol, 30%) was obtained as a
colorless wad after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ
[ppm] = 8.38−8.37 (m, 2H, H-h′/H-i′); 7.90−7.89 (m, 2H, H-h′/H-
i′); 7.66 (d, 4JH,H = 1.2 Hz, 1H, H-6); 7.48−7.39 (m, 4H, H-c′, H-c);
7.25−7.22 (m, 2H, H-d′); 7.09−7.07 (m, 2H, H-d); 6.96 (ddd, 3JH,H =
3.5 Hz, 3JH,H = 1.8 Hz,
4JH,H = 1.8 Hz, 1H, H-1′); 6.40−6.39 (m 1H,
H-3′); 5.84 (ddd, 3JH,H = 6.0 Hz, 3JH,H = 3.4 Hz, 4JH,H = 3.4 Hz, 1H, H-
2′); 5.16−5.11 (m, 4H, H-a, H-a′); 4.96 (bs, 1H, H-4′); 4.24−4.17 (m,
1H, H-5′); 2.25 (s, 3H, CH3); 1.90 (s, 3H, H-7). 13C NMR (150
MHz, MeOH-d4): δ [ppm] = 171.1 (C-f); 166.6 (C-4); 165.3 (C-f′);
152.9 (C-2); 152.4 (C-e/Ce′); 152.3 (C-e/C-e′); 138.7 (C-6); 135.9
(C-j′); 135.4 (C-b′); 135.3 (C-3′); 135.0 (C-b); 134.4 (C-g′); 131.8
(C-h′/C-i′); 130.5 (d, 4JC,P = 4.6 Hz, C-c′); 130.4 (d, 4JC,P = 5.5 Hz,
C-c); 127.6 (C-2′); 126.9 (C-h′/C-i′); 124.3 (CF3); 122.9 (C-d′);
122.9 (C-d); 112.0 (C-5); 90.8 (C-1′); 86.9 (d, 3JC,P = 9.5 Hz, C-4′);
70.2 (C-a, C-a′); 68.1 (C-5′); 20.6 (CH3); 12.5 (C-7). 19F NMR (565
MHz, MeOH-d4): δ/ppm = −60.75. 31P NMR (243 MHz, D2O,
decoupled): δ/ppm = −12.1 (d, 2JP,P = 20.4 Hz, Pβ); −12.9 (d, 2JP,P =
19.8 Hz, Pα). HRMS (ESI
−, m/z) calcd for C34H30F3N2O14P2:
809.1130 [M − H+]−. Found: 809.1096. Rp18-HPLC: method A, tR =
15.8 min.
Tetrabutylmmonium-CH3/CH3-Ph-DiPPro-d4TDP 7e. General
procedure E; phosphoramidite 5e (190 mg, 0.35 mmol), d4T
monophosphate (150 mg, 0.24 mmol), and 4,5-dicyanoimidazole
activator solution (1.20 mL, 0.30 mmol) in 6 mL of acetonitrile.
Oxidation by addition of tert-butyl hydroperoxide (5.5 M solution in n-
decane, 64 μL, 0.35 mmol). The product (115 mg, 0.115 mmol, 48%)
was obtained as a colorless wad. 1H NMR (600 MHz, D2O): δ [ppm]
= 8.07−8.06 (m 2H, H-h′); 7.67 (d, 4JH,H = 1.1 Hz, 1H, H-6); 7.47−
7.39 (m 4H, H-c, H-c′); 7.38−7.37 (m, 2H, H-d/H-d′); 7.20−7.18
(m, 2H, H-d/H-d′); 7.09−7.07 (m, 2H, H-i′); 6.96 (ddd, 3JH,H = 3.6
Hz, 3JH,H = 1.7 Hz,
4JH,H = 1.7 Hz, 1H, H-1′); 6.40 (ddd, 3JH,H = 6.0
Hz, 3JH,H = 3.2 Hz,
4JH,H = 3.2 Hz, 1H, H-3′); 5.84 (ddd, 3JH,H = 6.0
Hz, 3JH,H = 3.4 Hz,
4JH,H = 3.4 Hz, 1H, H-2′); 5.16−5.11 (m, 4H, H-a,
H-a′); 4.96 (bs, 1H, H-4′); 4.25−4.17 (m, 2H, H-5′); 3.24−3.21 (m,
8H, H-A); 2.45 (s, 3H, H-k′); 2.25 (s, 3H, CH3); 1.90 (d, 4JH,H = 1.1
Hz, 3H, H-7); 1.68−1.62 (m, 8H, H-B); 1.41 (dq, 3JH,H = 7.4 Hz, 3JH,H
= 7.4 Hz, 8H, H-C); 1.02 (t, 3JH,H = 7.4 Hz, 12H, H-D).
13C NMR
(150 MHz, D2O): δ [ppm] = 171.0 (C-f); 166.6 (C-4); 166.5 (C-f′);
152.8 (C-2); 152.6 (C-e/C-e′); 152.4 (C-e/C-e′); 146.2 (C-g′); 138.7
(C-6); 135.3 (C-3′); 135.1 (dd, 3JC,P = 7.5 Hz, 5JC,P = 3.3 Hz, C-b/C-
b′); 135.1 (dd, 3JC,P = 7.2 Hz, 5JC,P = 2.8 Hz, C-b/C-b′); 131.2 (C-h′);
130.5 (C-i′); 130.5 (d, 4JC,P = 5.5 Hz, C-c′); 130.4 (d, 4JC,P = 4.7 Hz,
C-c); 128.0 (C-j′); 127.6 (C-2′); 123.0 (C-d); 122.9 (C-d′); 112.1 (C-
5); 90.8 (C-1′); 87.0 (d, 3JC,P = 9.4 Hz, C-4′); 70.2 (d, 2JC,P = 5.6 Hz,
C-a); 70.2 (d, 2JC,P = 5.0 Hz, C-a′); 68.1 (d, 2JC,P = 6.2 Hz, C-5′); 59.5,
59.5, 59.5 (C-A); 24.8 (C-B); 21.7 (C-k′); 20.9 (CH3); 20.7 (C-C);
13.9 (C-D); 12.5 (C-7). 31P NMR (243 MHz, D2O, decoupled): δ/
ppm = −12.1 (d, 2JP,P = 20.6 Hz, Pβ); −12.9 (d, 2JP,P = 20.8 Hz, Pα).
HRMS (ESI−, m/z) calcd for C34H33N2O14P2: 755.1413 [M − H+]−.
Found: 755.1413. RP18-HPLC: method A, tR = 15.4 min.
Ammonium-C4H9/C7H15-DiPPro-d4TDP 8a. General procedure
E; phosphoramidite 5f (112 mg, 0.19 mmol), d4T monophosphate
(79 mg, 0.13 mmol), and 4,5-dicyanoimidazole activator solution (760
μL, 0.19 mmol) in 3 mL of acetonitrile. Oxidation by addition of tert-
butyl hydroperoxide (5.5 M solution in n-decane, 35 μL, 0.19 mmol).
The product (76 mg, 0.092 mmol, 71%) was obtained as a colorless
wad after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ [ppm] =
7.76 (s, 1H, H-6); 7.40−7.37 (m, 4H, H-c, H-c′); 7.06−7.04 (m, 4H,
H-d, H-d′); 6.95 (bs, 1H, H-1′); 6.39−6.38 (m, 1H, H-3′); 5.84−5.83
(m, 1H, H-2′); 5.11−5.09 (m, 4H, H-a, H-a′); 4.95 (bs, 1H, H-4′);
4.22−4.15 (m, 2H, H-5′); 2.60−2.56 (m, 4H, H-g, H-g′); 1.89 (s, 3H,
H-7); 1.71 (dt, 3JH,H = 7.7 Hz,
3JH,H = 7.5 Hz, 4H, H-h, H-h′); 1.48−
1.30 (m, 10H, H-i, H-i′−H-l′); 0.99 (t, 3JH,H = 7.4 Hz, 3H, H-j); 0.92
(t, 3JH,H = 6.7 Hz, 3H, H-m′). 13C NMR (150 MHz, MeOH-d4): δ
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[ppm] = 173.8 (C-f, C-f′); 166.7 (C-4); 152.4 (C-2); 152.4 (C-e, C-
e′); 138.7 (C-6); 135.3 (C-3′); 134.9 (d, 3JC,P = 2.4 Hz, C-b′/C-b);
134.9 (d, 3JC,P = 3.2 Hz, C-b′/C-b); 130.4 (d, 4JC,P = 4.5 Hz, C-c/C-
c′); 127.6 (C-2′); 122.9 (C-d, C-d′); 112.1 (C-5); 90.8 (C-1′); 86.9
(d, 3JC,P = 9.0 Hz, C-4′); 70.2 (2 ×d, 2JC,P = 5.0 Hz, 2JC,P = 4.2 Hz, C-a,
C-a′); 68.1 (d, 3JC,P = 6.1 Hz, C-5′); 35.0 (C-g′); 34.8 (C-g); 32.9,
30.1, 30.1, 23.7, (C-i′−C-l′); 28.1 (C-h); 26.0 (C-h′); 23.5 (C-i); 14.4
(C-m′); 14.1 (C-j); 12.5 (C-7). 31P NMR (243 MHz, MeOH-d4,
decoupled): δ/ppm = −12.07 (d, 2JP,P = 20.5 Hz, 1P, Pβ); −12.91 (d,
2JP,P = 20.5 Hz, 1P, Pα). HRMS (ESI
+, m/z) calcd for
C37H48N2O14P2Na: 829.2478 [M + Na]
+. Found: 829.2411. RP18-
HPLC: method A, tR = 18.8 min.
Ammonium-C4H9/C9H19-DiPPro-d4TDP 8b. General procedure
E; phosphoramidite 5g (164 mg, 0.27 mmol), d4T monophosphate
(111 mg, 0.18 mmol), and 4,5-dicyanoimidazole activator solution
(1.07 mL, 0.27 mmol) in 4 mL of acetonitrile. Oxidation by addition
of tert-butyl hydroperoxide (5.5 M solution in n-decane, 49 μL, 0.27
mmol). The product (115 mg, 0.14 mmol, 75%) was obtained as a
colorless wad after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ
[ppm] = 7.65 (s, 1H, H-6); 7.40−7.37 (m, 4H, H-c, H-c′); 7.06−7.04
(m, 4H, H-d, H-d′); 6.95−9.95 (m, 1H, H-1′); 6.38−6.37 (m, 1H, H-
3′); 5.84−5.83 (m, 1H, H-2′); 5.11−5.09 (m, 4H, H-a, H-a′); 4.95 (bs,
1H, H-4′); 4.22−4.14 (m, 2H, H-5′); 2.58, 2.58 (2 × t, 3JH,H = 7.4 Hz,
3JH,H = 7.3 Hz 4H, H-g, H-g′); 1.89 (s, 3H, H-7); 1.72 (dt, 3JH,H = 7.6
Hz, 3JH,H = 7.4 Hz, 4H, H-h, H-h′); 1.49−1.31 (m, 14H, H-i, H-i′−H-
n′); 0.99 (t, 3JH,H = 7.4 Hz, 3H, H-j); 0.90 (t, 3JH,H = 6.7 Hz, 3H, H-
o′). 13C NMR (150 MHz, MeOH-d4): δ [ppm] = 173.8 (C-f/C-f′);
173.8 (C-f/C-f′); 166.5 (C-4); 152.8 (C-2); 152.4 (C-e/C-e′); 152.4
(C-e/C-e′); 138.7 (C-6); 135.3 (C-3′); 134.9 (d, 3JC,P = 7.7 Hz, C-b′/
C-b); 134.9 (d, 3JC,P = 6.8 Hz, C-b′/C-b); 130.4 (d, 4JC,P = 3.8 Hz, C-
c/C-c′); 127.6 (C-2′); 122.9 (C-d, C-d′); 112.1 (C-5); 90.8 (C-1″);
86.9 (d, 3JC,P = 9.3 Hz, C-4’); 70.3 (d,
2JC,P = 5.2 Hz, C-a/C-a′); 70.2
(d, 2JC,P = 5.3 Hz, C-a/C-a′); 68.1 (d, 3JC,P = 6.3 Hz, C-5′); 35.0 (C-
g′); 34.8 (C-g); 33.0, 30.6, 30.4, 30.2, 23.7, (C-i′−C-n′); 28.1 (C-h);
26.0 (C-h′); 23.2 (C-i); 14.4 (C-o′); 14.1 (C-j); 12.5 (C-7). 31P NMR
(243 MHz, MeOH-d4, decoupled): δ/ppm = −12.06 (d, 2JP,P = 20.5
Hz, 1P, Pβ); −12.88 (d, 2JP,P = 20.5 Hz, 1P, Pα). HRMS (ESI−, m/z)
calcd for C39H51N2O14P2: 833.2821 [M − H+]−. Found: 833.2638.
RP18-HPLC: method A, tR = 20.2 min.
Ammonium-C4H9/C11H23-DiPPro-d4TDP 8c. General procedure
E; phosphoramidite 5h (42 mg, 0.058 mmol), d4T monophosphate
(33 mg, 0.053 mmol), and 4,5-dicyanoimidazole activator solution
(230 μL, 0.053 mmol) in 2 mL of acetonitrile. Oxidation by addition
of tert-butyl hydroperoxide (5.5 M solution in n-decane, 11 μL, 0.058
mmol). The product (33 mg, 0.038 mmol, 71%) was obtained as a
colorless wad after ion exchange. 1H NMR (600 MHz, D2O): δ [ppm]
= 7.66 (d, 4JH,H = 1.2 Hz, 1H, H-6); 7.40−7.37 (m, 4H, H-c, H-c′);
7.06−7.04 (m, 4H, H-d, H-d′); 6.95 (ddd, 3JH,H = 3.5 Hz, 3JH,H = 1.7
Hz, 4JH,H = 1.7 Hz, 1H, H-1′); 6.38 (ddd, 3JH,H = 6.0 Hz, 3JH,H = 3.4
Hz, 4JH,H = 3.4 Hz, 1H, H-3′); 5.83 (ddd, 3JH,H = 5.6 Hz, 3JH,H = 1.8
Hz, 4JH,H = 1.8 Hz, 1H, H-2′); 5.11−5.08 (m, 4H, H-a, H-a′); 4.95 (bs,
1H, H-4′); 4.23−4.15 (m, 2H, H-5′); 2.60−2.56 (m, 4H, H-g, H-g′);
1.89 (d, 4JH,H = 1.1 Hz, 3H, H-7); 1.76−1.69 (m, 4H, H-h, H-h′);
1.49−1.1.27 (m, 18H, H-i, H-i′-H-p′); 0.99 (t, 3JH,H = 7.4 Hz, 3H, H-
j); 0.99 (t, 3JH,H = 6.7 Hz, 3H, H-q′). 13C NMR (150 MHz, D2O): δ
[ppm] = 173.6 (C-f, C-f′); 166.5 (C-4); 152.8 (C-2); 152.3 (C-e, C-
e′); 138.7 (C-6); 133.9 (C-3′); 134.8 (C-b′, C-b); 130.4 (C-c, C-c′);
127.3 (C-2′); 122.9 (C-d, C-d′); 112.1 (C-5); 90.8 (C-1′); 86.9 (C-
4′); 70.2 (C-a, C-a′); 68.1 (C-5′); 35.0 (C-g′); 34.8 (C-g); 32.9, 30.7,
30.6, 30.4, 30.2, 23.5, (C-i′−C-p′); 28.0 (C-h); 25.8 (C-h′); 22.9 (C-
i); 14.2 (C-q′); 13.8 (C-j); 12.2 (C-7). 31P NMR (243 MHz, D2O,
decoupled): δ/ppm = −12.1 (d, 2JP,P = 20.6 Hz, Pβ); −12.9 (d, 2JP,P =
21.5 Hz, Pα). HRMS (ESI
+, m/z) calcd for C41H53N2O14P2Na:
885.3104 [M + Na]+. Found: 885.3022. RP18-HPLC: method A, tR =
21.4 min.
Ammonium-C4H9/CF3-Ph-DiPPro-d4TDP 8d. General proce-
dure E; phosphoramidite 5i (180 mg, 0.29 mmol), d4T mono-
phosphate (121 mg 0.19 mmol), and 4,5-dicyanoimidazole activator
solution (950 μL, 0.24 mmol) in 5 mL of acetonitrile. Oxidation by
addition of tert-butyl hydroperoxide (5.5 M solution in n-decane, 53
μL, 0.29 mmol). The product (89 mg, 0.10 mmol, 53%) was obtained
as a colorless wad after ion exchange. 1H NMR (600 MHz, MeOH-
d4): δ [ppm] = 8.38−8.37 (m, 2H, H-h′/H-i′); 7.90−7.89 (m, 2H, H-
h′/H-i′); 7.67 (d, 4J = 1.0 Hz, 1H, H-6); 7.47−7.44 (m, 2H, H-c′);
7.42−7.38 (m, 2H, H-c); 7.24−7.22 (m, 2H, H,d′); 7.07−7.05 (m,
2H, H-d); 6.96 (ddd, 3JH,H = 3.5 Hz,
3JH,H = 1.7 Hz,
4JH,H = 1.7 Hz,
1H, H-1′); 6.41−6.39 (m 1H, H-3′); 5.85−5.84 (m, 1H, H-2′); 5.16−
5.11 (m, 4H, H-a, H-a′); 4.96 (bs, 1H, H-4′); 4.25−4.17 (m, 1H, H-
5′); 2.56 (t, 3JH,H = 7.4 Hz, 2H, H-g); 1.90 (s, 3H, H-7); 1.70−1.66
(m, 2H, H-h); 1.46−1.39 (m, 2H, H-i); 0.96 (t, 3JH,H = 7.4 Hz, 3H, H-
j). 13C NMR (150 MHz, MeOH-d4): δ [ppm] = 173.9 (C-f); 166.9
(C-4); 165.3 (C-f′); 152.9 (C-2); 152.6 (C-e); 152.4 (C-e′); 138.9 (C-
6); 136.1 (C-j′); 135.6 (C-b′); 135.1 (C-b); 135.0 (C-3′); 134.5 (C-
g′); 131.8 (C-h′/C-i′); 130.5 (d, 4JC,P = 5.5 Hz, C-c′); 130.4 (d, 4JC,P =
5.6 Hz, C-c); 127.6 (C-2′); 126.9 (C-h′/C-i′); 124.3 (CF3); 122.9 (C-
d′); 122.9 (C-d); 112.4 (C-5); 90.6 (C-1′); 87.0 (d, 3JC,P = 9.3 Hz, C-
4′); 70.2 (C-a, C-a′); 68.1 (C-5′); 34.7 (C-g); 28.0 (C-h); 23.1 (C-i);
14.0 (C-j); 12.5 (C-7). 19F NMR (565 MHz, MeOH-d4): δ/ppm =
−60.75. 31P NMR (243 MHz, MeOH-d4, decoupled): δ/ppm = −12.1
(bs, Pβ); −12.9 (d, 2JP,P = 20.8 Hz, Pα). 19F NMR (565 MHz, MeOH-
d4): δ/ppm = −60.75. HRMS (ESI− , m/z) calcd for
C37H36F3N2O14P2: 851.1559 [M − H+]−. Found: 851.1597. RP18-
HPLC: method A, tR = 17.4 min.
Ammonium-C4H9/CH3-Ph-DiPPro-d4TDP 8e. General proce-
dure E; phosphoramidite 5j (123 mg, 0.21 mmol), d4T mono-
phosphate (89 mg, 0.14 mmol), and 4,5-dicyanoimidazole activator
solution (860 μL, 0.21 mmol) in 4 mL of acetonitrile. Oxidation by
addition of tert-butyl hydroperoxide (5.5 M solution in n-decane, 39
μL, 0.21 mmol). The product (36 mg, 0.044 mmol, 31%) was obtained
as a colorless wad after ion exchange. 1H NMR (600 MHz, D2O): δ
[ppm] = 8.07−8.06 (m 2H, H-h′); 7.67 (d, 4JH,H = 1.2 Hz, 1H, H-6);
7.45−7.38 (m 6H, H-c, H-c′, H-d/H-d′); 7.20−7.18 (m, 2H, H-d/H-
d′); 7.07−7.04 (m, 2H, H-i′); 6.96 (ddd, 3JH,H = 3.5 Hz, 3JH,H = 1.7
Hz, 4JH,H = 1.7 Hz, 1H, H-1′); 6.40 (ddd, 3JH,H = 6.0 Hz, 3JH,H = 3.3
Hz, 4JH,H = 3.3 Hz, 1H, H-3′); 5.84 (ddd, 3JH,H = 5.9 Hz, 3JH,H = 3.5
Hz, 4JH,H = 3.5 Hz, 1H, H-2′); 5.15−5.10 (m, 4H, H-a, H-a′); 4.96 (bs,
1H, H-4′); 4.25−4.16 (m, 2H, H-5′); 2.56 (t, 2H, H-g); 2.46 (s, 3H,
H-k′); 1.90 (d, 4JH,H = 1.1 Hz, 3H, H-7); 1.72−1.65 (m, 2H, H-h);
1.41 (m, 2H, H-i); 0.96 (t, 3JH,H = 7.4 Hz, 3H, H-j).
13C NMR (150
MHz, D2O): δ [ppm] = 173.6 (C-f); 166.6 (C-4); 166.5 (C-f′); 152.7
(C-2); 152.5 (C-e/C-e′); 152.3 (C-e/C-e′); 146.2 (C-g′); 138.6 (C-
6); 135.2 (C-3′); 135.1 (C-b/C-b′); 134.9 (C-b/C-b′); 131.2 (C-h′);
131.2 (C-c, C-c′); 130.5 (C-i′); 130.4 (C-j′); 127.6 (C-2′); 123.0 (C-
d); 122.9 (C-d′); 112.1 (C-5); 90.8 (C-1′); 87.0 (d, 3JC,P = 9.4 Hz, C-
4′); 70.3 (C-a, C-a′); 68.1 (C-5′); 34.7 (C-g); 27.9 (C-h); 23.2 (C-i);
21.6 (C-k′); 13.8 (C-j); 12.4 (C-7). 31P NMR (243 MHz, D2O,
decoupled): δ/ppm = −12.1 (d, 2JP,P = 20.2 Hz, Pβ); −12.9 (d, 2JP,P =
21.0 Hz, Pα). HRMS (ESI
−, m/z) calcd for C37H39N2O14P2: 797.1882
[M − H+]−. Found: 797.1855. RP18-HPLC: method A, tR = 17.0 min.
Ammonium-CH3/C7H15-DiPPro-AZTDP 9a. General procedure
E; phosphoramidite 5a (130 mg, 0.24 mmol), AZT monophosphate
(82 mg, 0.16 mmol), and 4,5-dicyanoimidazole activator solution (960
μL, 0.24 mmol) in 3 mL of acetonitrile. Oxidation by addition of tert-
butyl hydroperoxide (5.5 M solution in n-decane, 44 μL, 0.24 mmol).
The product (79 mg, 0.096 mmol, 60%) was obtained as a colorless
wad after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ [ppm] =
7.721 (s, 1H, H-6); 7.42−7.40 (m, 4H, H-c, H-c′); 7.08−7.05 (m, 4H,
H-d, H-d′); 6.21 (dd, 3JH,H = 6.8 Hz, 3JH,H = 6.8 Hz, 1H, H-1′); 5.14−
5.11 (m, 4H, H-a, H-a′); 4.41−4.39 (m, 1H, H-3′); 4.21−4.18 (m, 1H,
H-5′a); 4.13−4.10 (m, 1H, H-5′b); 4.04−4.03 (m, 1H, H-4′); 2.58 (t,
3JH,H = 7.4 Hz, 2H, H-g′); 2.36−2.31 (m, 2H, H-2′a); 2.30−2.26 (m,
2H, H-2′b); 2.27 (s, 3H, CH3); 1.90 (s, 3H, H-7); 1.73 (dt, 3JH,H = 7.4
Hz, 3JH,H = 7.4 Hz, 2H, H-h′); 1.44−1.30 (m, 8H, H-i′−H-l′); 0.92 (t,
3JH,H = 6.8 Hz, 3H, H-m′). 13C NMR (150 MHz, MeOH-d4): δ [ppm]
= 173.8 (C-f′); 171.0 (C-f); 166.4 (C-4); 152.5 (C-e/Ce′); 152.4 (C-
e/Ce′); 152.3 (C-2); 137.7 (C-6); 134.9 (C-b′, C-b); 130.5 (d, 4JC,P =
3.2 Hz, C-c/C-c′); 130.4 (d, 4JC,P = 3.3 Hz, C-c/C-c′); 122.9 (C-d, C-
d′); 112.2 (C-5); 85.8 (C-1′); 84.4 (d, 3JC,P = 9.4 Hz, C-4′); 70.3 (d,
2JC,P = 5.2 Hz, C-a/C-a′); 67.2 (d, 3JC,P = 5.5 Hz, C-5′); 62.5 (C-3′);
38.0 (C-2′); 35.0 (C-g′); 32.9, 30.1, 30.1, 23.7 (C-i′−C-l′); 26.0 (C-
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h′); 20.9 (CH3); 14.4 (C-m′); 12.6 (C-7). 31P NMR (243 MHz,
MeOH-d4, decoupled): δ/ppm = −12.14 (d, 2JP,P = 20.1 Hz, 1P, Pβ);
−12.76 (d, 2JP,P = 20.3 Hz, 1P, Pα). HRMS (ESI+, m/z) calcd for
C34H44N5O14P2: 808.2355 [M + H
+]+. Found: 808.2354. RP18-HPLC:
method B, tR = 17.4 min.
Ammonium-CH3/C9H19-DiPPro-AZTDP 9b. General procedure
E; phosphoramidite 5b (100 mg, 0.18 mmol), AZT monophosphate
(73 mg, 0.12 mmol), and 4,5-dicyanoimidazole activator solution (700
μL, 0.18 mmol) in 3 mL of acetonitrile. Oxidation by addition of tert-
butyl hydroperoxide (5.5 M solution in n-decane, 32 μL, 0.18 mmol).
The product (45 mg, 0.053 mmol, 45%) was obtained as a colorless
wad after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ [ppm] =
7.72 (s, 1H, H-6); 7.42−7.40 (m, 4H, H-c, H-c′); 7.08−7.05 (m, 4H,
H-d, H-d′); 6.21 (dd, 3JH,H = 6.8 Hz, 3JH,H = 6.8 Hz, 1H, H-1′); 5.14−
5.11 (m, 4H, H-a, H-a′); 4.40 (dt, 3JH,H = 6.6 Hz, 3JH,H = 6.8 Hz, 1H,
H-3′); 4.21−4.18 (m, 1H, H-5′a); 4.13−4.10 (m, 1H, H-5′b); 4.04−
4.03 (m, 1H, H-4′); 2.57 (t, 3JH,H = 7.4 Hz, 2H, H-g′); 2.36−2.31 (m,
2H, H-2′a); 2.30−2.26 (m, 2H, H-2′b); 2.27 (s, 3H, CH3); 1.90 (s,
3H, H-7); 1.73 (dt, 3JH,H = 7.4 Hz,
3JH,H = 7.4 Hz, 2H, H-h′); 1.45−
1.29 (m, 12H, H-i′−H-n′); 0.99 (t, 3JH,H = 7.4 Hz, 3H, H-j); 0.90 (t,
3JH,H = 6.8 Hz, 3H, H-o′). 13C NMR (150 MHz, MeOH-d4): δ [ppm]
= 173.7 (C-f′); 170.1 (C-f); 166.3 (C-4); 152.5 (C-e, Ce′); 152.4 (C-
2); 137.8 (C-6); 134.9 (C-b′, C-b); 130.5 (C-c, C-c′); 122.9 (C-d, C-
d′); 112.1 (C-5); 85.8 (C-1′); 84.4 (d, 3JC,P = 9.6 Hz, C-4′); 70.3 (d,
2JC,P = 6.4 Hz, C-a/C-a′); 67.3 (d, 3JC,P = 5.8 Hz, C-5′); 62.5 (C-3′);
38.0 (C-2′); 35.0 (C-g′); 33.0, 30.6, 30.4, 30.2, 23.8 (C-i′−C-n′); 26.0
(C-h′); 14.5 (C-o′); 12.6 (C-7). 31P NMR (243 MHz, MeOH-d4,
decoupled): δ/ppm = −12.16 (d, 2JP,P = 20.2 Hz, 1P, Pβ); −12.79 (d,
2JP,P = 19.8 Hz, 1P, Pα). HRMS (ESI
+, m/z) calcd for C36H48N5O14P2:
863.2668 [M + H+]+. Found: 836.2854. RP18-HPLC: method B, tR =
18.6 min.
Ammonium-CH3/C11H23-DiPPro-AZTDP 9c. General procedure
E; phosphoramidite 5c (125 mg, 0.21 mmol), AZT monophosphate
(86 mg, 0.14 mmol), and 4,5-dicyanoimidazole activator solution (830
μL, 0.21 mmol) in 4 mL of acetonitrile. Oxidation by addition of tert-
butyl hydroperoxide (5.5 M solution in n-decane, 38 μL, 0.21 mmol).
The product (58 mg, 0.066 mmol, 48%) was obtained as a colorless
wad after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ [ppm] =
7.72 (s, 1H, H-6); 7.42−7.40 (m, 4H, H-c, H-c′); 7.08−7.05 (m, 4H,
H-d, H-d′); 6.21 (dd, 3JH,H = 6.8 Hz, 3JH,H = 6.8 Hz, 1H, H-1′); 5.14−
5.12 (m, 4H, H-a, H-a′); 4.4 (dt, 3JH,H = 6.5 Hz, 3JH,H = 6.7 Hz, 1H, H-
3′); 4.21−4.18 (m, 1H, H-5′a); 4.13−4.10 (m, 1H, H-5′b); 4.04−4.03
(m, 1H, H-4′); 2.58 (d, 3JH,H = 7.4 Hz, 1H, H-g′); 2.36−2.26 (m, 2H,
H-2′a, H-2′b); 2.27 (s, 3H, CH3); 1.90 (s, 3H, H-7); 1.76−1.71 (m,
2H, H-h′); 1.45−1.25 (m, 16H, H-i′−H-p′); 0.90 (t, 3JH,H = 6.9 Hz,
3H, H-q′). 13C NMR (150 MHz, MeOH-d4): δ [ppm] = 173.8 (C-f′);
171.0 (C-f); 166.3 (C-4); 152.5 (C-e, Ce′); 152.3 (C-2); 137.8 (C-6);
134.8 (C-b′, C-b); 130.5 (2 ×d, 4JC,P = 2.3 Hz, C-c, C-c′); 122.9 (C-d,
C-d′); 112.2 (C-5); 85.8 (C-1′); 84.4 (d, 3JC,P = 8.8 Hz, C-4′); 70.3 (d,
2JC,P = 5.3 Hz, C-a/C-a′); 67.3 (d, 3JC,P = 5.8 Hz, C-5′); 62.5 (C-3′);
38.0 (C-2′); 35.0 (C-g′); 33.1, 30.7, 30.6, 30.5, 30.4, 30.2, 23.7 (C-i′−
C-p′); 26.0 (C-h′); 20.9 (CH3); 12.6 (C-7). 31P NMR (243 MHz,
MeOH-d4, decoupled): δ/ppm = −12.17 (d, 2JP,P = 20.5 Hz, 1P, Pβ);
−12.8 (d, 2JP,P = 20.4 Hz, 1P, Pα). HRMS (ESI+, m/z) calcd for
C38H51N5O14P2Na: 864.2981 [M + Na]
+. Found: 864.2982. RP18-
HPLC: method B, tR = 20.1 min.
Ammonium-CH3/Ph-CF3-DiPPro-AZTDP 9d. General procedure
E; phosphoramidite 5d (140 mg, 0.24 mmol), AZT monophosphate
(98 mg, 0.16 mmol), and 4,5-dicyanoimidazole activator solution (940
μL, 0.24 mmol) in 4 mL of acetonitrile. Oxidation by addition of tert-
butyl hydroperoxide (5.5 M solution in n-decane, 44 μL, 0.24 mmol).
The product (83 mg, 0.095 mmol, 61%) was obtained as a colorless
wad after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ [ppm] =
8.38−8.36 (m, 2H, H-h′/H-i′); 7.90−7.89 (m, 2H, H-h′/H-i′); 7.73
(s, 1H, H-6); 7.50−7.48 (m, 2H, H-c′); 7.45−7.42 (m, 2H, H-c);
7.25−7.23 (m, 2H, H-d′); 7.10−7.08 (m, 2H, H-d); 6.22 (dd, 3JH,H =
6.8 Hz, 3JH,H = 6.8 Hz, 1H, H-1′); 5.18−5.14 (m, 4H, H-a, H-a′);
4.43−4.40 (m, 1H, H-3′); 4.23−4.20 (m, 1H, H-5′a); 4.15−4.12 (m,
1H, H-5′b); 4.06−4.04 (m, 1H, H-4′); 2.36−2.26 (m, 2H, H-2′a, H-
2′b); 2.25 (s, 3H, CH3); 1.90 (s, 3H, H-7). 13C NMR (150 MHz,
MeOH-d4): δ [ppm] = 171.0 (C-f); 166.4 (C-4); 165.4(C-f′); 152.4
(C-2); 152.3 (C-e); 152.3 (C-e′); 137.8 (C-6); 135.9 (C-j′); 135.3 (C-
b′); 135.1 (C-b); 134.4 (C-g′); 131.8 (C-h′/C-i′); 130.6 (d, 5JC,P = 4.2
Hz, C-c′); 130.1 (d, 5JC,P = 2.5 Hz, C-c); 126.5 (C-h′/C-i′); 124.4
(CF3); 123.0 (C-d′); 122.9 (C-d); 112.2 (C-5); 85.8 (C-1′); 84.4 (d,
3JC,P = 9.5 Hz, C-4′); 70.4 (d, 2JC,P = 5.3 Hz, C-a/C-a′); 70.3 (d, 2JC,P =
5.5 Hz, C-a/C-a′); 67.3 (d, 3JC,P = 5.8 Hz, C-5′); 62.5 (C-3′); 38.0 (C-
2′); 20.9 (CH3); 12.6 (C-7). 17F NMR (565 MHz, MeOH-d4): δ/ppm
= −64.7. 31P NMR (243 MHz, MeOH-d4, decoupled): δ/ppm =
−12.14 (d, 2JP,P = 20.1 Hz, 1P, Pβ); −12.68−12.83 (m, 1P, Pα). HRMS
(ESI+, m/z) calcd for C34H33F3N5O14P2: 854.1451 [M + H
+]+. Found:
854.1442. RP18-HPLC: method B, tR = 16.4 min.
Ammonium-C4H9/C7H15-DiPPro-AZTDP 10a. General proce-
dure E; phosphoramidite 5f (132 mg, 0.23 mmol), AZT mono-
phosphate (96 mg, 0.15 mmol), and 4,5-dicyanoimidazole activator
solution (900 μL, 0.23 mmol) in 4 mL of acetonitrile. Oxidation by
addition of tert-butyl hydroperoxide (5.5 M solution in n-decane, 42
μL, 0.23 mmol). The product (37 mg, 0.043 mmol, 29%) was obtained
as a colorless wad after ion exchange. 1H NMR (600 MHz, MeOH-
d4): δ [ppm] = 7.71 (s, 1H, H-6); 7.42−7.40 (m, 4H, H-c, H-c′);
7.07−7.05 (m, 4H, H-d, H-d′); 6.20 (dd, 3JH,H = 6.7 Hz, 3JH,H = 6.7
Hz, 1H, H-1′); 5.13−5.11 (m, 4H, H-a, H-a′); 4.40−4.38 (m, 1H, H-
3′); 4.21−4.18 (m, 1H, H-5′a); 4.13−4.09 (m, 1H, H-5′b); 4.03 (bs,
1H, H-4′); 2.59−2.56 (m, 4H, H-g, H-g′); 2.36−2.31 (m, 2H, H-2′a);
2.30−2.26 (m, 2H, H-2′b); 1.90 (s, 3H, H-7); 1.72 (dt, 3JH,H = 7.6 Hz,
3JH,H = 7.6 Hz 4H, H-h, H-h′); 1.48−1.29 (m, 10H, H-i, H-i′−H-l′);
0.98 (t, 3JH,H = 7.4 Hz, 3H, H-j); 0.92 (t,
3JH,H = 6.6 Hz, 3H, H-m′).
13C NMR (150 MHz, MeOH-d4): δ [ppm] = 173.7 (C-f, C-f′); 166.4
(C-4); 152.5 (C-e, Ce′); 152.3 (C-2); 137.8 (C-6); 134.9 (C-b/C-b′);
134.8 (C-b/C-b′); 130.5 (C-c, C-c′); 122.9 (C-d, C-d′); 112.2 (C-5);
85.8 (C-1′); 84.4 (d, 3JC,P = 9.4 Hz, C-4′); 70.4 (d, 2JC,P = 5.6 Hz, C-a/
C-a′); 67.2 (d, 3JC,P = 6.1 Hz, C-5′); 62.5 (C-3′); 38.0 (C-2′); 35.0 (C-
g/C-g′); 34.8 (C-g/c-g′); 32.9, 30.1, 30.1, 23.7 (C-i′−C-l′); 28.1 (C-h,
C-h′); 26.0 (C-h, C-h′); 23.2 (C-i) 14.4 (C-m′); 14.1 (C-j); 12.6 (C-
7). 1H NMR (600 MHz, MeOH-d4): δ [ppm] = 7.71 (s, 1H, H-6);
7.42−7.40 (m, 4H, H-c, H-c′); 7.07−7.05 (m, 4H, H-d, H-d′); 6.20
(dd, 3JH,H = 6.7 Hz,
3JH,H = 6.7 Hz, 1H, H-1′); 5.13−5.11 (m, 4H, H-a,
H-a′); 4.40−4.38 (m, 1H, H-3′); 4.21−4.18 (m, 1H, H-5′a); 4.13−
4.09 (m, 1H, H-5′b); 4.03 (bs, 1H, H-4′); 2.59−2.56 (m, 4H, H-g, H-
g′); 2.36−2.31 (m, 2H, H-2′a); 2.30−2.26 (m, 2H, H-2′b); 1.90 (s,
3H, H-7); 1.72 (dt, 3JH,H = 7.6 Hz,
3JH,H = 7.6 Hz 4H, H-h, H-h′);
1.48−1.29 (m, 10H, H-i, H-i′−H-l′); 0.98 (t, 3JH,H = 7.4 Hz, 3H, H-j);
0.92 (t, 3JH,H = 6.6 Hz, 3H, H-m′). HRMS (ESI+, m/z) calcd for
C37H49N5O14P2Na: 872.2643 [M + Na]
+. Found: 872.2568.
Ammonium-C4H9/C9H19-DiPPro-AZTDP 10b. General proce-
dure E; phosphoramidite 5g (117 mg, 0.191 mmol), AZT mono-
phosphate (79 mg, 0.13 mmol), and 4,5-dicyanoimidazole activator
solution (760 μL, 0.19 mmol) in 3 mL of acetonitrile. Oxidation by
addition of tert-butyl hydroperoxide (5.5 M solution in n-decane, 35
μL, 0.91 mmol). The product (97 mg, 0.11 mmol, 85%) was obtained
as a colorless wad after ion exchange. 1H NMR (600 MHz, MeOH-
d4): δ [ppm] = 7.72 (s, 1H, H-6); 7.42−7.40 (m, 4H, H-c, H-c′);
7.06−7.05 (m, 4H, H-d, H-d′); 6.21 (dd, 3JH,H = 6.8 Hz, 3JH,H = 6.8
Hz, 1H, H-1′); 5.14−5.11 (m, 4H, H-a, H-a′); 4.40 (dt, 3JH,H = 6.7 Hz,
3JH,H = 6.8 Hz, 1H, H-3′); 4.21−4.18 (m, 1H, H-5′a); 4.13−4.10 (m,
1H, H-5′b); 4.04−4.03 (m, 1H, H-4′); 2.59−2.56 (m, 4H, H-g, H-g′);
2.36−2.31 (m, 2H, H-2′a); 2.30−2.26 (m, 2H, H-2′b); 1.90 (s, 3H, H-
7); 1.72 (dt, 3JH,H = 7.4 Hz,
3JH,H = 7.6 Hz 4H, H-h, H-h′); 1.48−1.29
(m, 14H, H-i, H-i′−H-n′); 0.99 (t, 3JH,H = 7.4 Hz, 3H, H-j); 0.91 (t,
3JH,H = 6.8 Hz, 3H, H-o′). 13C NMR (150 MHz, MeOH-d4): δ [ppm]
= 173.7 (C-f, C-f′); 166.5 (C-4); 152.5 (C-e, Ce′); 152.4 (C-2); 137.8
(C-6); 134.8 (C-b′, C-b); 130.5 (C-c, C-c′) 122.9 (C-d, C-d′); 112.2
(C-5); 85.8 (C-1′); 84.4 (d, 3JC,P = 8.8 Hz, C-4′); 70.4 (d, 2JC,P = 5.5
Hz, C-a/C-a′); 67.3 (d, 3JC,P = 5.5 Hz, C-5′); 62.5 (C-3′); 38.0 (C-2′);
35.0 (C-g/C-g′); 34.8 (C-g/c-g′); 33.0, 30.6, 30.4, 30.2, 23.7 (C-i′−C-
n′); 28.1 (C-h, C-h′); 26.0 (C-h, C-h′); 23.3 (C-i); 14.4 (C-o′); 14.1
(C-j); 12.6 (C-7). 31P NMR (243 MHz, MeOH-d4, decoupled): δ/
ppm = −12.16 (d, 2JP,P = 20.6 Hz, 1P, Pβ); −12.78 (d, 2JP,P = 21.7 Hz,
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1P, Pα). HRMS (ESI
+, m/z) calcd for C39H53N5O14P2Na: 900.2962
[M + Na]+. Found: 900.2946. RP18-HPLC: method B, tR = 20.5 min.
Ammonium-C4H9/C11H23-DiPPro-AZTDP 10c. General proce-
dure E; phosphoramidite 5h (120 mg, 0.17 mmol), AZT mono-
phosphate (69 mg, 0.11 mmol), and 4,5-dicyanoimidazole activator
solution (550 μL, 0.14 mmol) in 3 mL of acetonitrile. Oxidation by
addition of tert-butyl hydroperoxide (5.5 M solution in n-decane, 31
μL, 0.17 mmol). The product (37 mg, 0.040 mmol, 37%) was obtained
as a colorless wad after ion exchange. 1H NMR (600 MHz, MeOH-
d4): δ [ppm] = 7.75 (s, 1H, H-6); 7.21−7.12 (m, 4H, H-c, H-c′);
6.85−6.84 (m, 4H, H-d, H-d′); 6.00 (dd, 3JH,H = 6.8 Hz, 3JH,H = 6.8
Hz, 1H, H-1′); 4.92−4.90 (m, 4H, H-a, H-a′); 4.19 (dt, 3JH,H = 6.6 Hz,
3JH,H = 6.8 Hz, 1H, H-3′); 4.00−3.97 (m, 1H, H-5′a); 3.92−3.89 (m,
1H, H-5′b); 3.83−3.82 (m, 1H, H-4′); 2.38−2.35 (m, 4H, H-g, H-g′);
2.15−2.10 (m, 2H, H-2′a); 2.08−2.05 (m, 2H, H-2′b); 1.69 (s, 3H, H-
7); 1.55−1.48 (m, 4H, H-h, H-h′); 1.28−1.08 (m, 18H, H-i, H-i′−H-
p′); 0.78 (t, 3JH,H = 7.4 Hz, 3H, H-j); 0.69 (t, 3JH,H = 6.9 Hz, 3H, H-
q′). 13C NMR (150 MHz, MeOH-d4): δ [ppm] = 173.3 (C-f, C-f′);
166.4 (C-4); 152.5 (C-e, Ce′); 152.4 (C-2); 137.8 (C-6); 134.9 (C-b′,
C-b); 130.5 (d, C-c, C-c′); 122.9 (C-d, C-d′); 112.1 (C-5); 85.8 (C-
1′); 84.4 (d, 3JC,P = 9.4 Hz, C-4′); 70.3 (d, 2JC,P = 5.5 Hz, C-a/C-a′);
67.3 (d, 3JC,P = 5.9 Hz, C-5′); 62.5 (C-3′); 38.0 (C-2′); 35.0 (C-g/c-
g′); 34.8 (C-g/c-g′); 33.1, 30.7, 30.6, 30.5, 30.4, 30.2, 23.3 (C-i,C-i′−
C-p′); 28.1 (C-h, C-h′); 26.0 (C-h, C-h′); 14.1 (C-j); 14.5 (C-q′);
12.6 (C-7). 31P NMR (243 MHz, MeOH-d4, decoupled): δ/ppm =
−12.16 (d, 2JP,P = 20.3 Hz, 1P, Pβ); −12.78 (d, 2JP,P = 20.4 Hz, 1P, Pα).
HRMS (ESI+, m/z) calcd for C41H57N5O14P2Na: 928.3275 [M + Na]
+.
Found: 928.3252. RP18-HPLC: method B, tR = 21.9 min.
Ammonium-C4H9/CF3-Ph-DiPPro-AZTDP 10d. General proce-
dure E; phosphoramidite 5i (179 mg, 0.282 mmol), AZT mono-
phosphate (117 mg, 0.188 mmol), and 4,5-dicyanoimidazole activator
solution (1.13 mL, 0.282 mmol) in 5 mL of acetonitrile. Oxidation by
addition of tert-butyl hydroperoxide (5.5 M solution in n-decane, 51
μL, 0.282 mmol). The product (80 mg, 0.088 mmol, 47%) was
obtained as a colorless wad after ion exchange. 1H NMR (600 MHz,
MeOH-d4): δ [ppm] = 8.38−8.36 (m, 2H, H-h′/H-i′); 7.90−7.89 (m,
2H, H-h′/H-i′); 7.73 (s, 1H, H-6); 7.49−7.47 (m, 2H, H-c′); 7.44−
7.41 (m, 2H, H-c); 7.25−7.23 (m, 2H, H-d′); 7.08−7.06 (m, 2H, H-
d); 6.22 (dd, 3JH,H = 6.8 Hz,
3JH,H = 6.8 Hz, 1H, H-1′); 5.18−5.13 (m,
4H, H-a, H-a′); 4.43−4.41 (m, 1H, H-3′); 4.23−4.21 (m, 1H, H-5′a);
4.15−4.12 (m, 1H, H-5′b); 4.06−4.05 (m, 1H, H-4′); 2.56 (t, 3JH,H =
7.4 Hz, 2H, H-g); 2.37−2.32 (m, 1H, H-2′a); 2.31−2.27 (m, 1H, H-
2′b); 1.90 (s, 3H, H-7); 1.68 (dt, 3JH,H = 7.4 Hz, 3JH,H = 7.6 Hz, 2H, H-
h); 1.43 (dq, 3JH,H = 7.5 Hz,
3JH,H = 7.5 Hz, 2H, H-i); 0.96 (t,
3JH,H =
7.4 Hz, 2H, H-j). 13C NMR (150 MHz, MeOH-d4): δ [ppm] = 173.6
(C-f); 166.3 (C-4); 166.3 (C-f′); 152.4 (C-2); 152.3 (C-e); 152.2 (C-
e′); 137.4 (C-6); 135.9 (C-j′); 135.3 (C-b′); 134.8 (C-b); 134.3 (C-
g′); 131.6 (C-h′/C-i′); 130.6 (d, 4JC,P = 4.2 Hz, C-c′); 130.1 (d, 4JC,P =
2.5 Hz, C-c); 126.5 (C-h′/C-i′); 124.3 (CF3); 122.6 (C-d′); 122.6 (C-
d); 112.1 (C-5); 85.4 (C-1′); 84.4 (d, 3JC,P = 9.2 Hz, C-4′); 70.4 (2
×d, 2JC,P = 6.3 Hz,
2JC,P = 4.9 Hz C-a, C-a′); 67.3 (d, 3JC,P = 5.6 Hz, C-
5′); 62.2 (C-3′); 37.8 (C-2′b); 37.7 (C-2′a); 34.4 (C-g); 27.7 (C-h);
22.9 (C-i); 14.1 (C-j); 12.4 (C-7). 19F NMR (565 MHz, MeOH-d4):
δ/ppm = −65.7. 31P NMR (243 MHz, MeOH-d4, decoupled): δ/ppm
= −12.14 (d, 2JP,P = 20.2 Hz, 1P, Pβ); −12.67−12.81 (m, 1P, Pα).
HRMS (ESI+, m/z) calcd for C37H39F3N5O14P2: 896.1921 [M + H]
+.
Found: 896.1914. RP18-HPLC: method B, tR = 18.0 min.
Ammonium-C4H9-DiPPro-AZTDP 11a. General procedure E;
symmetric bis(4-pentanoyloxymethyl)-N,N-diisopropylamino-
phosphoramidite (133 mg, 0.243 mmol), AZT monophosphate (101
mg, 0.162 mmol), and 4,5-dicyanoimidazole activator solution (970
μL, 0.243 mmol) in 4 mL of acetonitrile. Oxidation by addition of tert-
butyl hydroperoxide (5.5 M solution in n-decane, 44 μL, 0.243 mmol).
The product (84 mg, 0.10 mmol, 63%) was obtained as a colorless wad
after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ [ppm] = 7.72
(s, 1H, H-6); 7.42−7.40 (m, 4H, H-c); 7.07−7.05 (m, 4H, H-d); 6.21
(dd, 3JH,H = 6.8 Hz,
3JH,H = 6.8 Hz, 1H, H-1′); 5.14−5.11 (m, 4H, H-
a); 4.41−4.39 (m, 1H, H-3′); 4.21−4.18 (m, 1H, H-5′a); 4.13−4.10
(m, 1H, H-5′b); 4.04−4.03 (m, 1H, H-4′); 2.58 (t, 3JH,H = 7.4 Hz, 2H,
H-g); 2.36−2.26 (m, 2H, H-2′); 1.90 (s, 3H, H-7); 1.74−1.69 (m 2H,
H-h); 1.49−1.43 (m, 2H, H-i); 0.99 (t, 3JH,H = 7.4 Hz, 6H, H-j). 13C
NMR (150 MHz, MeOH-d4): δ [ppm] = 173.7 (C-f); 166.4 (C-4);
152.5 (C-e); 152.3 (C-2); 137.8 (C-6); 134.9 (C-b); 130.5 (d, 4JC,P =
2.3 Hz, C-c); 122.9 (C-d′); 122.6 (C-d); 112.2 (C-5); 85.8 (C-1′);
84.4 (d, 3JC,P = 9.0 Hz, C-4′); 70.3 (d, 2JC,P = 6.1 Hz C-a); 67.3 (d,
3JC,P = 5.8 Hz, C-5′); 62.5 (C-3′); 38.0 (C-2′); 34.8 (C-g); 28.1 (C-h);
23.3 (C-i); 14.1 (C-j); 12.6 (C-7). [α]D
23 7 (c 0.1 mg/mL, CH3OH).
31P NMR (243 MHz, MeOH-d4, decoupled): δ/ppm = −12.2 (d, 2JP,P
= 20.4 Hz, Pβ); −12.8 (d, 2JP,P = 20.5 Hz, Pα). HRMS (ESI+, m/z)
calcd for C34H44N5O14P2: 808.2355 [M + H]
+. Found: 808.2352.
RP18-HPLC: method B, tR = 17.4 min.
Ammonium-C6H13-DiPPro-AZTDP 11b. General procedure E;
symmetric bis(4-heptanoyloxymethyl)-N,N-diisopropylamino-
phosphoramidite (217 mg, 0.36 mmol), AZT monophosphate (150
mg, 0.24 mmol), and 4,5-dicyanoimidazole activator solution (1.44
mL, 0.36 mmol) in 6 mL of acetonitrile. Oxidation by addition of tert-
butyl hydroperoxide (5.5 M solution in n-decane, 66 μL, 0.36 mmol).
The product (83 mg, 0.09 mmol, 39%) was obtained as a colorless wad
after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ [ppm] = 7.72
(s, 1H, H-6); 7.42−7.40 (m, 4H, H-c); 7.07−7.05 (m, 4H, H-d); 6.21
(dd, 3JH,H = 6.8 Hz,
3JH,H = 6.8 Hz, 1H, H-1′); 5.14−5.11 (m, 4H, H-
a); 4.41−4.39 (m, 1H, H-3′); 4.21−4.18 (m, 1H, H-5′a); 4.13−4.10
(m, 1H, H-5′b); 4.03 (bs, 1H, H-4′); 2.58 (t, 3JH,H = 7.4 Hz, 2H, H-g);
2.36−2.26 (m, 2H, H-2′); 1.90 (s, 3H, H-7); 1.75−1.70 (m 2H, H-h);
1.44−1.41 (m, 2H, H-i); 1.37−1.36 (m, 8H, H-j, H-k); 0.93 (t, 3JH,H =
6.6 Hz, 6H, H-l). 13C NMR (150 MHz, MeOH-d4): δ [ppm] = 173.7
(C-f); 166.4 (C-4); 152.5 (C-e); 152.4 (C-2); 137.8 (C-6); 134.9 (C-
b); 130.5 (d, 4JC,P = 2.2 Hz, C-c); 122.9 (C-d′); 122.6 (C-d); 112.2
(C-5); 85.8 (C-1′); 84.4 (d, 3JC,P = 9.1 Hz, C-4′); 70.3 (d, 2JC,P = 6.0
Hz C-a); 67.3 (d, 3JC,P = 6.1 Hz, C-5′); 62.5 (C-3′); 38.0 (C-2′); 35.0
(C-g); 32.7 (C-j/C-k); 29.9 (C-i); 25.9 (C-h); 23.6 (C-j/C-k); 14.4
(C-l); 12.6 (C-7). [α]D
23 12 (c 0.1 mg/mL, CH3OH).
31P NMR (243
MHz, MeOH-d4, decoupled): δ/ppm = −12.2 (d, 2JP,P = 20.9 Hz, Pβ);
−12.8 (d, 2JP,P = 21.4 Hz, Pα). HRMS (ESI+, m/z) calcd for
C38H52N5O14P2: 864.2991 [M + H]
+. Found: 864.2978. RP18-HPLC:
method B, tR = 20.0 min.
Ammonium-C9H19-DiPPro-AZTDP 11c. General procedure E;
symmetric bis(4-decanoyloxymethyl)-N,N-diisopropylamino-
phosphoramidite (120 mg, 0.18 mmol), AZT monophosphate (72
mg, 0.12 mmol), and 4,5-dicyanoimidazole activator solution (720 μL,
0.18 mmol) in 3 mL of acetonitrile. Oxidation by addition of tert-butyl
hydroperoxide (5.5 M solution in n-decane, 33 μL, 0.18 mmol). The
product (58 mg, 0.060 mmol, 50%) was obtained as a colorless wad
after ion exchange. 1H NMR (600 MHz, MeOH-d4): δ [ppm] = 7.72
(s, 1H, H-6); 7.42−7.39 (m, 4H, H-c); 7.06−7.04 (m, 4H, H-d); 6.21
(dd, 3JH,H = 6.8 Hz,
3JH,H = 6.8 Hz, 1H, H-1′); 5.13−5.11 (m, 4H, H-
a); 4.41−4.39 (m, 1H, H-3′); 4.21−4.18 (m, 1H, H-5′a); 4.13−4.10
(m, 1H, H-5′b); 4.04 (bs, 1H, H-4′); 2.57 (t, 3JH,H = 7.4 Hz, 4H, H-g);
2.36−2.29 (m, 4H, H-2′); 1.90 (s, 3H, H-7); 1.76−1.71 (m 4H, H-h);
1.43−1.31 (m, 24H, H-i - H-n); 0.91 (t, 3JH,H = 6.8 Hz, 6H, H-o). 13C
NMR (150 MHz, MeOH-d4): δ [ppm] = 173.7 (C-f); 166.5 (C-4);
152.6 (C-e); 152.5 (C-2); 137.8 (C-6); 134.9 (C-b); 130.5 (C-c);
122.9 (C-d); 112.2 (C-5); 85.8 (C-1′); 84.4 (d, 3JC,P = 9.5 Hz, C-4′);
70.4 (d, 2JC,P = 5.8 Hz C-a); 67.3 (d,
3JC,P = 5.9 Hz, C-5′); 62.5 (C-3′);
38.0 (C-2′); 35.0 (C-g); 33.1, 30.6, 30.4, 30.2, 23.7 (C-i - C-n); 26.0
(C-h); 14.4 (C-o); 12.6 (C-7). [α]D
23 37 (c 0.1 mg/mL, CH3OH).
31P
NMR (243 MHz, MeOH-d4, decoupled): δ/ppm = −12.2 (d, 2JP,P =
20.4 Hz, Pβ); −12.8 (d, 2JP,P = 20.4 Hz, Pα). HRMS (ESI+, m/z) calcd
for C44H64N5O14P2: 948.3930 [M + H]
+. Found: 948.3915. RP18-
HPLC: method B, tR = 24.4 min.
Compounds Evaluation Methods. Hydrolysis Studies in
Phosphate Buffer at pH 7.3. Hydrolysis was started by addition
of 300 μL of 50 mM phosphate buffer (547 mg (3.85 mol), disodium
hydrogen phosphate, and 155 mg (0.890 mol) of potassium
dihydrogen phosphate, filling up with water to 100 mL. The pH was
adjusted by addition of NaOH or phosphoric acid to 300 μL of 1.9
mM solution of the DiPPro-NDP in DMSO. The hydrolysis solution
was incubated at 37 °C. Aliquots were taken at certain points of time
and frozen in liquid nitrogen. Directly after unfreezing analysis was
followed by analytical RP-18-HPLC.
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Hydrolysis Studies in CEM/0 Cell Extracts. An amount of 50 μL
CEM/0 cell extracts was mixed with 10 μL of water. By addition of 10
μL of a 6 mM solution of the DiPPro-NDP in DMSO, the hydrolysis
was started. Six to eight of these samples were prepared and incubated
at 37 °C for different periods of time. Hydrolysis was stopped by
quenching with 150 μL of methanol. After 5 min on ice, 5 min in an
ultrasonic bath, and centrifugation at 13 000 rpm (Heraeus, Biofuge
Pico) the samples were filtered and frozen in liquid nitrogen until an
amount of 35 μL was injected into the analytical RP-18-HPLC
instrument. Hydrolysis was monitored for a maximum of 10 h.
Hydrolysis Studies in RPMI Medium. An amount of 50 μL of
RPMI-culture medium without FCS was mixed with 10 μL of water.
By addition of 10 μL of a 6 mM solution of the DiPPro-NDP in
DMSO, the hydrolysis was started. Six to eight of these samples were
prepared and incubated at 37 °C for different periods of time. After a
period of time an amount of 150 μL of methanol was added and the
sample was frozen in liquid nitrogen until an amount of 35 μL was
injected into the analytical RP-18-HPLC instrument.
Hydrolysis Studies with PLE. An amount of 10 μL of a 6 mM
solution of the DiPPro-NDP in DMSO was mixed with 15 μL of
DMSO and 100 μL of 50 mM phosphate buffer. By addition of 7.5 μL
of PLE solution (3 mg/mL in PBS, 17 units/mg), the hydrolysis was
started. Hydrolysis was stopped by quenching with 132.5 μL of
methanol. After 5 min on ice, 5 min in an ultrasonic bath, and
centrifugation at 13 000 rpm (Heraeus, Biofuge Pico) the samples
were filtered and frozen in liquid nitrogen until an amount of 35 μL
was injected into the analytical RP-18-HPLC instrument.
Preparation of CEM Cell Extracts. Human CD4+ T-lymphocyte
CEM cells were grown in RPMI-1640-based cell culture medium to a
final density of about 3 × 106 cells/mL. After centrifugation for 10 min
at 1250 rpm (Heraeus, Megafuge 3.0R) at 4 °C, washing twice with
cold phosphate buffered saline (PBS), the pellet was resuspended at
108 cells/mL and sonicated three times for 10 s. After a second
centrifugation of this suspension at 10 000 rpm (Heraeus, Megafuge
3.0R) the supernatant was divided into aliquots and frozen to −80 °C
until used.
Antiviral Assay. Inhibition of HIV-1(IIIB)- and HIV-2(ROD)-
induced cytopathogenicity in wild-type CEM/0 or thymidine kinase-
deficient CEM/TK− cell cultures was measured in microtiter 96-well
plates containing ∼3 × 105 CEM cells/mL infected with 100 CCID50
of HIV per milliliter and containing appropriate dilutions of the test
compounds. After 4−5 days of incubation at 37 °C in a CO2-
controlled humidified atmosphere, CEM giant (syncytium) cell
formation was examined microscopically. EC50 (50% effective
concentration) was defined as the compound concentration required
to inhibit HIV-induced giant cell formation by 50%.
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